UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2018
ALPHATEC HOLDINGS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 000-52024 | 20-2463898 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
5818 El Camino Real
Carlsbad, California 92008
(Address of Principal Executive Offices)
(760) 431-9286
(Registrants telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14.a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. | Entry into a Material Definitive Agreement |
On April 16, 2018, Alphatec Holdings, Inc. (the Company) entered into an Amended and Restated Registration Rights Agreement (the Amended Registration Agreement) amending the Registration Rights Agreement entered into by the Company on March 8, 2018 (the Original Registration Agreement) to permit the Company to file the Registration Statement contemplated by the Original Registration Agreement on or before April 16, 2018 and to add to the registrable securities thereunder 1,800,000 shares of common stock issuable by the Company upon exercise of a warrant to purchase common stock issued by the Company pursuant to a Warrant Exercise Agreement entered into by the Company on March 8, 2018.
The foregoing description of the Amended Registration Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Amended Registration Agreement, which is filed as Exhibit 4.1 to this Current Report on Form 8-K/A.
Item 2.01. | Completion of Acquisition or Disposal of Assets |
On March 12, 2018, the Company filed a Current Report on Form 8-K (the Original Form 8-K), to report the completion on March 8, 2018 of its acquisition of SafeOp Surgical, Inc. (SafeOp) pursuant to the terms of an Agreement and Plan of Merger (the Merger Agreement), dated as of March 6, 2018, among the Company, Safari Merger Sub, Inc., SafeOp, certain key stockholders of SafeOp and a stockholder representative.
This amendment to the Original Form 8-K is being filed to provide the financial statements and pro forma financial information required by Item 9.01(a) and (b) of Form 8-K relating to the Companys acquisition of SafeOp.
Item 9.01. | Financial Statements and Exhibits |
(a) Financial Statements of Businesses Acquired .
The audited financial statements of SafeOp Surgical, Inc., for the years ended December 31, 2016 and 2017 and the notes related thereto are filed as Exhibit 99.1 and are incorporated herein by reference.
(b) Pro Forma Financial Information .
The unaudited pro forma condensed combined financial statements of the Company as of December 31, 2017 are filed as Exhibit 99.2 and are incorporated herein by reference.
(d) Exhibits .
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 16, 2018 | ALPHATEC HOLDINGS, INC. | |||||
By: |
/s/ Jeffrey Black |
|||||
Name: | Jeffrey Black | |||||
Its: | Chief Financial Officer |
Exhibit 4.1
Execution Version
AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT
BY AND AMONG
ALPHATEC HOLDINGS, INC.
AND
EACH PURCHASER IDENTIFIED ON THE SIGNATURE PAGES HERETO
APRIL 16, 2018
TABLE OF CONTENTS
1. |
Definitions |
1 | ||||
2. |
Shelf Registration |
8 | ||||
3. |
Underwritten Offering of Initiating Holders |
11 | ||||
4. |
Registration and Other Procedures |
13 | ||||
5. |
Registration Expenses |
19 | ||||
6. |
Black-out Period |
20 | ||||
7. |
Indemnification |
21 | ||||
(a) |
Indemnification by the Company |
21 | ||||
(b) |
Indemnification by Holders |
22 | ||||
(c) |
Conduct of Indemnification Proceedings |
23 | ||||
(d) |
Contribution |
24 | ||||
8. |
Miscellaneous |
24 | ||||
(a) |
Remedies |
24 | ||||
(b) |
No Piggyback on Registrations; Prohibition on Filing Other Registration Statements |
25 | ||||
(c) |
[Reserved] |
25 | ||||
(d) |
Discontinued Disposition |
25 | ||||
(e) |
Piggy-Back Registrations |
25 | ||||
(f) |
Amendments and Waivers |
27 | ||||
(g) |
Notices |
27 | ||||
(h) |
Successors and Assigns |
28 | ||||
(i) |
No Inconsistent Agreements |
28 | ||||
(j) |
Execution and Counterparts |
28 | ||||
(k) |
Governing Law |
28 | ||||
(l) |
Cumulative Remedies |
29 | ||||
(m) |
Severability |
29 | ||||
(n) |
Headings |
29 | ||||
(o) |
Independent Nature of Holders Obligations and Rights |
29 |
AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT
This Amended and Restated Registration Rights Agreement (this Agreement ) is made and entered into as of April 16, 2018, between Alphatec Holdings, Inc., a Delaware corporation (the Company ), and each of the several persons signatory hereto (each such purchaser, a Purchaser and, collectively, the Purchasers ).
RECITALS
A. The parties hereto entered into a Registration Rights Agreement, dated as of March 8, 2018 (the Original Agreement ).
B. This Agreement amends and restates in accordance with Section 8(f) of the Original Agreement in one document certain changes to the Original Agreement with respect to the resetting of the Filing Date at April 16, 2018, and the addition of the Warrant Holder Warrant Shares (as defined herein) to the Registrable Securities (as defined herein).
C. This Agreement is made pursuant to the Securities Purchase Agreement, dated as of March 8, 2018, among the Company and the other parties thereto (the Purchase Agreement ), the Agreement and Plan of Merger, dated as of March 6, 2018 (the Merger Agreement ), among the Company, Safari Merger Sub, Inc., SafeOp Surgical, Inc. ( Target ) and the other parties thereto, and the Warrant Exercise Agreement, dated as of March 8, 2018, between the Company and Armistice Capital Master Fund, Ltd. (the Warrant Holder ).
AGREEMENT
The Company and each Purchaser hereby agree as follows:
1. Definitions .
As used in this Agreement, the following terms shall have the following meanings:
Action means any action, suit, inquiry, notice of violation, Proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign).
Advice shall have the meaning set forth in Section 8(d) .
1
Affiliate means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.
Agreement shall have the meaning set forth in the preamble.
Certificate of Designation means the Certificate of Designation of the Companys Series B Convertible Preferred Stock to be filed prior to the Closing by the Company with the Secretary of State of the State of Delaware, in the form of Exhibit A attached to the Purchase Agreement.
Closing shall have the meaning set forth in the Purchase Agreement.
Commission means the United States Securities and Exchange Commission.
Company shall have the meaning set forth in the preamble.
Common Stock means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.
Conversion Shares shall have the meaning ascribed to such term in the Certificate of Designation.
Effectiveness Date means, with respect to the Initial Registration Statement required to be filed hereunder, the 60th calendar day following March 8, 2018 (or, in the event of a full review by the Commission, the 90th calendar day following March 8, 2018) and with respect to any additional Registration Statements which may be required pursuant to Section 2(b) or Section 4(c) , the 75th calendar day following the date on which an additional Registration Statement is required to be filed hereunder (or, in the event of a full review by the Commission, the 110th calendar day following the date such additional Registration Statement is required to be filed hereunder); provided , however , that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comment, the Effectiveness Date as to such Registration Statement shall be the second Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above; provided , further , however , if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.
2
Effectiveness Period shall have the meaning set forth in Section 2(a) .
Event shall have the meaning set forth in Section 2(d)(v) .
Event Date shall have the meaning set forth in Section 2(d)(v) .
Exchange Act means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
Filing Date means, with respect to the Initial Registration Statement required hereunder, April 16, 2018 and, with respect to any additional Registration Statements which may be required pursuant to Section 2(b) or Section 4(c) , the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities; provided , however , that if the Filing Date falls on a day that is not a Trading Day, then the Filing Date shall be extended to the next succeeding Trading Day.
FINRA means the Financial Industry Regulatory Authority.
Holder or Holders means the holder or holders, as the case may be, from time to time of Registrable Securities, including any assignee of rights hereunder in accordance with the terms hereof.
Holder Underwritten Offering shall have the meaning set forth in Section 3(e) .
Indemnified Party shall have the meaning set forth in Section 7(c) .
Indemnifying Party shall have the meaning set forth in Section 7(c) .
Initial Registration Statement means the initial Registration Statement filed or to be filed pursuant to this Agreement.
Initiating Holders shall mean and include (i) the Lead Investor or (ii) any Holder or Holders (other than the Lead Investor) of more than 50% of the then Registrable Securities (not including the Lead Investors Registrable Securities); provided that such Holder or Holders (other than the Lead Investor) then own at least One Million (1,000,000) Registrable Securities.
Lead Investor shall mean L-5 Healthcare Partners, LLC, a Delaware limited liability company, and any assignee, in whole or in part, of its rights as a Lead Investor hereunder in accordance with the terms hereof.
Losses shall have the meaning set forth in Section 7(a) .
3
Merger Agreement shall have the meaning set forth in the Recitals.
Merger Closing Shares shall mean the shares of Common Stock of the Company valued in the aggregate at $8,666,667 pursuant to the valuation terms of the Merger Agreement, and issued to those Purchasers who are to receive such shares at the closing of the Merger Agreement.
Merger Warrant Shares shall mean the shares of Common Stock underlying those certain warrants to purchase Common Stock in the aggregate principal amount of $3,000,000, to be issued to those Purchasers who are to receive such warrants at the closing of the Merger Agreement.
Milestone Shares shall mean those shares of Common Stock which may be issued upon satisfaction of certain milestone achievements by the Company and Target, to those Purchasers who are to receive such Milestone Shares pursuant to the terms of the Merger Agreement.
Note Conversion Shares shall mean the shares of Common Stock underlying those certain convertible promissory notes in the aggregate principal amount of $3,000,000 (the Merger Notes ), to be issued to those Purchasers who are to receive such convertible promissory notes at the closing of the Merger Agreement.
Original Agreement shall have the meaning set forth in the Recitals.
Participating Holders shall have the meaning set forth in Section 3(b) .
Person means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
Piggy-Back Registration Statement shall have the meaning set forth in Section 8(e) .
Preferred Stock means up to 45,200 shares of the Companys Series B Convertible Preferred Stock issued under the Purchase Agreement having the rights, preferences and privileges set forth in the Certificate of Designation.
Proceeding means an Action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.
4
Prospectus means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including pre- and post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.
Purchase Agreement shall have the meaning set forth in the Recitals.
Purchaser(s) shall have the meaning set forth in the preamble.
Registrable Securities means, as of any date of determination, (a) all shares of Common Stock issued or issuable upon conversion of the Preferred Stock (as if on such date all shares of Preferred Stock are converted in full without regard to any conversion limitations in the Certificate of Designation), (b) all Warrant Shares then issued and issuable upon exercise of the Warrants (as if on such date the Warrants are exercised in full without regard to any exercise limitations therein), (c) all Merger Closing Shares, (d) all Note Conversion Shares, (e) all Merger Warrant Shares (as if on such date the Merger Warrants are exercised in full without regard to any exercise limitations therein), (f) all Milestone Shares, (g) all Warrant Holder Warrant Shares (as if on such date the Warrant Holder Warrants are exercised in full without regard to any exercise limitations therein), (h) any securities that may be issued or distributed or be issuable or distributable in respect of, or in substitution for, the foregoing upon any stock split, dividend or other distribution, recapitalization or similar event with respect to any of the foregoing, and (i) any other shares of Common Stock then owned by any Purchaser provided that, with respect to any Purchaser other than the Lead Investor, such Purchaser is at the time of registration an Affiliate of the Company; provided , however , that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as (x) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (y) such Registrable Securities have been previously sold in accordance with Rule 144 and new certificates for them not bearing a legend restricting transfer shall have been delivered by the Company, or (z), with respect to any Purchaser other than the
5
Lead Investor, such securities become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, are not, at the time of sale, and have not been during the preceding three months, an Affiliate of the Company, and all Warrants are exercised by cashless exercise as provided in Section 2(c) of each of the Warrants), as reasonably determined by the Company, upon the advice of counsel to the Company.
Registration Statement means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration statements contemplated by Section 2(b) or Section 4(c) , including, in each case, the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.
Rule 144 means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
Rule 415 means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
Rule 424 means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
SEC Guidance means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii) the Securities Act.
Securities means the Preferred Stock and the Warrants.
Securities Act means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
6
Selling Stockholder Questionnaire shall have the meaning set forth in Section 4(a) .
Special Registration shall have the meaning set forth in Section 3(e) .
Stockholder Approval shall have the meaning set forth in the Purchase Agreement.
Subscription Amount means, as to each Purchaser, the aggregate amount to be paid for Preferred Stock and Warrants purchased under the Purchase Agreement.
Subsidiary means any subsidiary of the Company as set forth on Schedule 3.1(a) to the Purchase Agreement and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after March 8, 2018.
Target shall have the meaning set forth in the Recitals.
Trading Day means a day on which the principal Trading Market is open for trading.
Trading Market means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, and the New York Stock Exchange (or any successors to any of the foregoing).
Transaction Documents shall have the meaning set forth in the Purchase Agreement.
Transfer Agent means Computershare, Inc., the current transfer agent of the Company, with a mailing address of 480 Washington Avenue, Jersey City, New Jersey 07310, and any successor transfer agent of the Company.
Underwritten Offering means a registration in which securities of the Company are sold to an underwriter or underwriters on a firm commitment basis for reoffering to the public.
Warrant Holder shall have the meaning set forth in the Recitals.
Warrant Holder Warrant Shares means the shares of Common Stock issuable upon exercise of the Warrant Holder Warrants.
7
Warrant Holder Warrants means, those certain warrants granted to the Warrant Holder to purchase up to 1,800,000 shares of Common Stock, exercisable at $3.50 per share.
Warrant Shares means the shares of Common Stock issuable upon exercise of the Warrants.
Warrants means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.3(a) of the Purchase Agreement, which Warrants shall be exercisable immediately upon Stockholder Approval and have a term of exercise equal to five years from the date of such Stockholder Approval, in the form of Exhibit D attached to the Purchase Agreement.
2. Shelf Registration .
(a) On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance herewith, subject to the provisions of Section 2(e)); provided , however , that no Holder shall be required to be named as an underwriter without such Holders express prior written consent. If pursuant to SEC Guidance, such alternative appropriate form requires Holder to be named as an underwriter, and Holder chooses not to give consent to be so named, the Companys obligations under this subsection register on another appropriate form shall be waived. Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under Section 4(c) ) to be declared effective under the Securities Act as promptly as reasonably practicable after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all Registrable Securities shall cease to be Registrable Securities as provided herein (the Effectiveness Period ). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. Eastern Time on a Trading Day. The Company shall immediately notify the Holders via facsimile or by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. Eastern Time on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such
8
notification of effectiveness or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(d)(iv) .
(b) Notwithstanding the registration obligations set forth in Section 2(a) , if all of the Registrable Securities cannot be registered for resale as a secondary offering on a single Registration Statement, the Company agrees to promptly inform each of the Holders thereof and use its best efforts (i) to file additional Registration Statements as may be available pursuant to SEC Guidance successively trying to register on each such Registration Statement the maximum number of remaining Registrable Securities permitted to be registered pursuant to SEC Guidance for resale, until all of the Registrable Securities have been registered for resale, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering, subject to the provisions of Section 2(e) with respect to filing on Form S-3 or other appropriate form, and subject to the provisions of Section 2(d)(iv) with respect to the payment of liquidated damages, and (ii) to have each such additional Registration Statement declared effective by the Commission as soon as practicable; provided , however , that prior to and following the filing of any such additional Registration Statements, the Company shall be obligated to use best efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance.
(c) Subject to the payment of liquidated damages pursuant to Section 2(d)(iv) , if, notwithstanding the Companys compliance with the provisions set forth in Section 2(b), the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering, unless otherwise directed to the Company in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:
(i) first, the Company shall reduce or eliminate any securities to be included other than Registrable Securities; and
(ii) second, the Company shall reduce Registrable Securities represented (applied, in the case that some Registrable Securities may be registered, to the Holders on a pro rata basis based on the total number of unregistered Registrable Securities held by such Holders).
In the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to such Holders allotment.
(d) If:
(i) the Initial Registration Statement is not filed on or prior to its Filing Date or if the Company files the Initial Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 4(a) ; or
9
(ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within two (2) Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be reviewed or will not be subject to further review; or
(iii) prior to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of such Registration Statement promptly (but in any event within ten (10) Trading Days) after the receipt of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective; or
(iv) a Registration Statement registering for resale all of the Registrable Securities is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement (provided, however, that if all Registrable Securities cannot be included in the Initial Registration Statement under conditions contemplated in Section 2(c), the liquidated damages provided for in this Section 2(d) shall not begin to accrue until the Effectiveness Date of any additional Registration Statement required to be filed hereunder, including pursuant to Section 2(b) or Section 4(c)); or
(v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason (other than due to the inaccuracy of any information regarding the Holders) to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate of twenty (20) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach set forth in clauses (i)-(v) being referred to as an Event , and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded, and for purpose of clause (v) the date on which such tenth (10th) or twentieth (20th) calendar day period, as applicable, is exceeded being referred to as Event Date ), then,
in addition to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.5% multiplied by the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement with respect to any Securities then held by, or issuable to, such Holder that are Registrable Securities. The parties agree that the maximum
10
aggregate liquidated damages payable to a Holder under this Agreement shall be 12% of the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement. If the Company fails to pay any partial liquidated damages pursuant to this Section 2(d) in full within seven days after the date payable, the Company will pay interest thereon at a rate of 15% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until and through the date such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.
(e) If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.
(f) Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or Affiliate of a Holder as any underwriter without the prior written consent of such Holder.
3. Underwritten Offering of Initiating Holders .
(a) Up to three (3) Underwritten Offerings for the Lead Investor and up to two (2) additional Underwritten Offerings for any other Initiating Holders of Registrable Securities pursuant to a Registration Statement may be initiated by an Initiating Holder, upon notice to the Company; provided that such Underwritten Offering is for at least Ten Million Dollars ($10,000,000) of Registrable Securities owned by the Initiating Holder and the Participating Holders (as defined below) in the aggregate.
(b) Upon any such request for an Underwritten Offering pursuant to Section 3(a), the Company shall (i) deliver to each Holder (other than the Initiating Holder) written notice of such contemplated Underwritten Offering and (ii) enter into an underwriting agreement with such underwriters for such offering, such agreement to be reasonably satisfactory in substance and form to the Company, the Initiating Holder and the underwriters, and to contain such representations and warranties by the Company and such other terms as are generally prevailing in agreements of that type, including indemnities no less favorable to the recipient thereof than those provided in Section 7. The Initiating Holder shall reasonably cooperate with the Company in the negotiation of such underwriting agreement and shall give consideration to the reasonable suggestions of the Company regarding the form thereof. The Holders participating in such Underwritten Offering (the Participating Holders ) shall be parties to such underwriting agreement, which underwriting agreement shall (x) contain such representations
11
and warranties by, and the other agreements on the part of, the Company to and for the benefit of such Participating Holders as are customarily made by issuers to selling stockholders in secondary underwritten public offerings and (y) provide that any or all of the conditions precedent to the obligations of such underwriters under such underwriting agreement also shall be conditions precedent to the obligations of such Participating Holders. Any such Participating Holder shall not be required to make any representations or warranties to or agreements with the Company or the underwriters in connection with such underwriting agreement other than representations, warranties or agreements regarding such Participating Holder, such Participating Holders title to the Registrable Securities, such Participating Holders authority to sell the Registrable Securities, such Participating Holders intended method of distribution, absence of liens with respect to the Registrable Securities, enforceability of the applicable underwriting agreement as against such Participating Holder, receipt of all consents and approvals with respect to the entry into such underwriting agreement and the sale of such Registrable Securities and any other representations required to be made by such Participating Holder under applicable law, rule or regulation, and the aggregate amount of the liability of such Participating Holder in connection with such underwriting agreement shall not exceed such Participating Holders gross proceeds from such Underwritten Offering (less underwriting discounts and commissions).
(c) Subject to the provisions of this Section 3 and Section 8(e), no Person may participate in any Underwritten Offering hereunder unless such Person (i) agrees to sell such Persons securities on the basis provided in any underwriting arrangements approved by the Initiating Holder and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements.
(d) In the case of an Underwritten Offering pursuant to this Section 3, the price, underwriting discount and other financial terms for the Registrable Securities shall be determined by the Initiating Holder. In addition, in the case of any Underwritten Offering, each of the applicable Holders may withdraw their request to participate in the registration pursuant to this Section 3 or Section 8(e) after being advised of such price, discount and other terms and shall not be required to enter into any agreements or documentation that would require otherwise.
(e) With respect to any Underwritten Offering of Registrable Securities by the Initiating Holder (each, a Holder Underwritten Offering ), the Company agrees not to effect (other than pursuant to the registration applicable to such Holder Underwritten Offering or pursuant to a Special Registration) any public sale or distribution, or to file any registration statement (other than pursuant to the registration applicable to such Holder Underwritten Offering or pursuant to a Special Registration) covering any of its equity securities or any securities convertible into or exchangeable or exercisable for such securities, during the period not to exceed ten (10) days prior and sixty (60) days following the effective date of such offering or such longer period up to ninety (90) days as may be requested by the managing underwriter
12
for such Holder Underwritten Offering. Special Registration means the registration of (i) equity securities and/or options or other rights in respect thereof solely registered on Form S-4 or Form S-8 (or successor form) or (i) shares of equity securities and/or options or other rights in respect thereof to be offered to directors, employees, consultants, customers, lenders or vendors of the Company or its Subsidiaries or in connection with dividend reinvestment plans.
(f) If the managing underwriter or underwriters of a proposed Underwritten Offering of the Registrable Securities pursuant to this Section 3 advise the Initiating Holder and the Company that, in its or their opinion, the number of securities requested to be included in such Underwritten Offering exceeds the number which can be sold in such offering without being likely to have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, the securities to be included in such Underwritten Offering (i) first , shall be allocated pro rata among the Participating Holders based on the relative number of Registrable Securities then held by each such Participating Holder (provided that any securities thereby allocated to a Participating Holder that exceed such Participating Holders request shall be reallocated among the remaining requesting Participating Holders in like manner), (ii) second , and only if all the securities referred to in clause (i) have been included in such Underwritten Offering, the number of securities that the Company proposes to include in such Underwritten Offering that, in the opinion of the managing underwriter or underwriters, can be sold without having such adverse effect, and (iii) third , and only if all the securities referred to in clause (ii) have been included in such Underwritten Offering, any other securities eligible for inclusion in such Underwritten Offering that, in the opinion of the managing underwriter or underwriters, can be sold without having such adverse effect.
4. Registration and Other Procedures .
In connection with the Companys registration and other obligations hereunder (including in connection with any Underwritten Offering), the Company shall:
(a) Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference, but not including (x) any Exchange Act filing or (y) any supplement or post-effective amendment to a registration statement that is not related to such Holders Registrable Securities), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders, and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. Notwithstanding the above, the Company shall not be obligated to provide the Holders advance copies of any
13
universal shelf registration statement registering securities in addition to those required hereunder, or any Prospectus prepared thereto. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Lead Investor or the Holders of a majority of the Registrable Securities (other than those Registrable Securities held by the Lead Investor) shall reasonably object in good faith, provided that, the Company is notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as Annex A (a Selling Stockholder Questionnaire ) on a date that is not less than four (4) Trading Days prior to the Filing Date or by the end of the fourth (4th) Trading Day following the date on which such Holder receives draft materials in accordance with this Section 4(a).
(b) (i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used in connection therewith (subject to any requirement that a post-effective amendment be declared effective by the Commission) as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities subject to any SEC Guidance that sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.
(c) If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such Registrable Securities.
14
(d) Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) and the underwriters, if any, as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed (but not including (i) any Exchange Act filing or (ii) any supplement or post-effective amendment to a registration statement that is not related to such Holders Registrable Securities), (B) when the Commission notifies the Company whether there will be a review of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; provided , however , in no event shall any such notice contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries and (vii) if, at any time, the representations and warranties of the Company in any applicable underwriting agreement cease to be true and correct in all material respects.
(e) Promptly incorporate in a Prospectus or post-effective amendment to the applicable Registration Statement such information as the managing underwriter or underwriters, if any, and the Holders agree should be included therein relating to the plan of distribution (including as may be required in connection with any Underwritten Offering) with respect to such Registrable Securities, and make all required filings of such Prospectus or post-effective
15
amendment as soon as reasonably practicable after being notified of the matters to be incorporated in such Prospectus or post-effective amendment.
(f) Use its best efforts to cause the Registrable Securities covered by the applicable Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the seller or sellers thereof or the underwriter or underwriters, if any, to consummate the disposition of such Registrable Securities.
(g) Enter into such customary agreements (including underwriting and indemnification agreements) and take all such other actions as any Holder or the managing underwriter or underwriters, if any, reasonably request in order to expedite or facilitate the registration and disposition of such Registrable Securities.
(h) Make such representations and warranties to the Holders and the underwriters or agents, if any, in form, substance and scope as are customarily made by issuers in secondary underwritten public offerings.
(i) Obtain for delivery to the Holders and to the underwriter or underwriters, if any, an opinion or opinions from counsel for the Company dated the effective date of the Registration Statement or, in the event of an Underwritten Offering, the date of the closing under the underwriting agreement, in customary form, scope and substance, which opinions shall be reasonably satisfactory to such Holders or underwriters, as the case may be, and their respective counsel.
(j) In the case of an Underwritten Offering, obtain for delivery to the Company and the managing underwriter or underwriters, with copies to the Participating Holders, a cold comfort letter from the Companys independent certified public accountants in customary form and covering such matters of the type customarily covered by cold comfort letters as the managing underwriter or underwriters reasonably request, dated the date of execution of the underwriting agreement and brought down to the closing under the underwriting agreement.
(k) Cooperate with each Holder and each underwriter, if any, participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with the FINRA.
(l) Provide and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by the applicable Registration Statement from and after a date not later than the effective date of such Registration Statement.
(m) Use its best efforts to cause all Registrable Securities covered by the applicable Registration Statement to be listed on NASDAQ and each other securities exchange
16
on which the Common Stock is then listed or quoted and on each inter-dealer quotation system on which any of the Common Stock is then quoted.
(n) Make available upon reasonable notice at reasonable times and for reasonable periods for inspection by any Holder, by any underwriter participating in any disposition to be effected pursuant to the applicable Registration Statement and by any attorney, accountant or other agent retained by such Holder or any such underwriter, all pertinent financial and other records, pertinent corporate documents and properties of the Company, and cause all of the Companys executive officers and the independent public accountants who have certified its financial statements to make themselves available to discuss the business of the Company and to supply all information reasonably requested by any such Person in connection with such Registration Statement as shall be necessary to enable them to exercise their due diligence responsibility; provided that any such Person gaining access to information regarding the Company pursuant to this Section 4(n) shall agree to hold in strict confidence and shall not make any disclosure or use any information regarding the Company that the Company determines in good faith to be confidential, and of which determination such Person is notified, unless (i) the release of such information is requested or required by law or by deposition, interrogatory, requests for information or documents by a governmental entity, subpoena or similar process, (ii) such information is or becomes publicly known other than through a breach of this or any other agreement of which such Person has actual knowledge, (iii) such information is or becomes available to such Person on a non-confidential basis from a source other than the Company or (iv) such information is independently developed by such Person.
(o) In the case of an Underwritten Offering, cause the senior executive officers of the Company to participate in the customary road show presentations that may be reasonably requested by the managing underwriter or underwriters in any such Underwritten Offering and otherwise to facilitate, cooperate with, and participate in each proposed offering contemplated herein and customary selling efforts related thereto.
(p) Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.
(q) Furnish to each Holder and each underwriter, if any, without charge, as many conformed copies of each such Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent reasonably requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided that any such item which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.
17
(r) Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 4(d) .
(s) Prior to any resale of Registrable Securities by a Holder, use its reasonable efforts to register or qualify, and cooperate with the selling Holders or underwriters, if any, and their respective counsel, in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable Securities for the resale under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder or underwriter, if any, or their respective counsel reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement; provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.
(t) If requested by a Holder, cooperate with such Holder or underwriter, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder or underwriter, if any, may request.
(u) Upon the occurrence of any event contemplated by Section 4(d) , as promptly as reasonably possible under the circumstances taking into account the Companys good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section 4(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 4(u) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise
18
required pursuant to Section 4(d) , for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.
(v) Otherwise use reasonable best efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.
(w) The Company shall use its reasonable best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the registration of the resale of Registrable Securities.
(x) The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days of the Companys request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.
5. Registration Expenses . All fees and expenses incident to the performance of, or compliance with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Companys counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company (and the underwriters in the case of an Underwritten Offering) in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by
19
the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holders; provided, that, in the event of any Underwritten Offering, the Company shall reimburse the Initiating Holder for the reasonable fees and expenses of one counsel.
6. Black-out Period . In the case of an offering of Registrable Securities pursuant to an Underwritten Offering, the Company and each of the Holders agree, if requested by the Initiating Holder or the managing underwriter or underwriters with respect to such Underwritten Offering, not to (a) offer for sale, sell, pledge, or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any Person at any time in the future of) any Common Stock (including Common Stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Commission and Common Stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for Common Stock; provided that, for the avoidance of doubt, this Section 6 shall not prohibit any Holder from exercising any Warrants or Merger Warrants, or any other warrants of the Company or converting any Preferred Stock or any other preferred stock of the Company, or converting any Merger Notes, in each case, in accordance with the terms and subject to the conditions in respect thereof, (b) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of Common Stock, whether any such transaction described in clauses (a) or (b) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise, (c) make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any Common Stock or securities convertible into or exercisable or exchangeable for Common Stock or any other securities of the Company or (d) publicly disclose the intention to do any of the foregoing, in each case, during the period beginning seven (7) days before, and ending ninety (90) days (or such lesser period as may be agreed by the Initiating Holder or, if applicable, the managing underwriter or underwriters) (or such other period as may be reasonably requested by the Initiating Holder or the managing underwriter or underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in the FINRA rules or any successor provisions or amendments thereto) after, the date of the underwriting agreement entered into in connection with such Underwritten Offering, to the extent timely notified in writing by the Initiating Holder or the managing underwriter or underwriters, as the case may be; provided that no Holder shall be subject to any
20
such black-out period of longer duration than that applicable to the Initiating Holder or any other Holder. Notwithstanding the foregoing, (i) the Company may effect a public sale or distribution of securities of the type described above and during the periods described above if such sale or distribution is made pursuant to Registrations on Form S-4 or S-8 or any successor form to such Forms or as part of any registration of securities for offering and sale to employees, directors or consultants of the Company and its Subsidiaries pursuant to any employee stock plan or other employee benefit plan arrangement, and (ii) the distribution of Registrable Securities by any Holder that is a non-natural person to such Holders equity holders or any transfer by any Holder to any Affiliate thereof shall not be prohibited by this Section 6 and shall be expressly permitted in any separate agreement the Holders shall be requested to execute to effectuate the prohibitions in this Section 6 (provided, in each case with respect to this clause (ii), that such transferee agrees in writing to be bound by the provisions of this Section 6 ). Without limiting the foregoing, if after March 8, 2018 the Company grants any Person (other than a Holder) any rights to demand or participate in a registration, the Company agrees that the agreement with respect thereto shall include such Persons agreement to comply with any black-out period required by this Section 6 as if it were a Holder hereunder. If requested by the managing underwriter or underwriters of any such Underwritten Offering, the Holders shall execute a separate agreement to the foregoing effect. The Company may impose stop-transfer instructions with respect to the Common Stock (or other securities) subject to the foregoing restriction until the end of the period referenced above.
7. Indemnification .
(a) Indemnification by the Company . The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys fees) and expenses (collectively, Losses ), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged
21
violation by the Company of any federal, state or common law or regulation (including the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder), in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holders proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto or (ii) in the case of an occurrence of an event of the type specified in Section 4(d)(iii)-(vi) , the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 8(d) . The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 8(h) .
(b) Indemnification by Holders . Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to such Holders information provided in the Selling Stockholder Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 7 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.
22
(c) Conduct of Indemnification Proceedings . If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an Indemnified Party ), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the Indemnifying Party ) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof; provided , that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.
An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.
Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section 7) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.
23
(d) Contribution . If the indemnification under Section 7(a) or Section 7(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section 7 was available to such party in accordance with its terms.
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 7(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 7 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.
The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.
8. Miscellaneous .
(a) Remedies . In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.
24
(b) No Piggyback on Registrations; Prohibition on Filing Other Registration Statements . Until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other registration statements, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their equivalents, until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, provided that this Section 8(b) shall not prohibit the Company from filing supplements or amendments to registration statements filed prior to the date of this Agreement.
(c) [ Reserved ]
(d) Discontinued Disposition . By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 4(d )( iii) through (vi) , such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the Advice ) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d )( iv) .
(e) Piggy-Back Registrations ; Underwritten Offerings .
(i) If, at any time during the Effectiveness Period, there is not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities (the Piggy-Back Registration Statement ), other than on Form S-4 or Form S-8 or one universal shelf registration statement on Form S-3 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with the Companys stock option or other employee benefit plans, then the Company shall deliver to each Holder a written notice of such determination and, if within fifteen (15) days after the date of the delivery of such notice, any such Holder shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities such Holder requests to be registered; provided , however , that the Company shall not be required to provide notice or otherwise register any Registrable Securities pursuant to this Section 8(e) that are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Commission pursuant to the Securities Act or that are the
25
subject of a then effective Registration Statement that is available for resales or other dispositions by such Holder. Notwithstanding the foregoing, (i) if such registration involves an Underwritten Offering, such Holder must sell such Registrable Securities that such Holder requests to be registered to, if applicable, the underwriter(s) at the same price and subject to the same underwriting discounts and commissions that apply to the other securities sold in such offering (it being acknowledged that the Company shall be responsible for other expenses as set forth in Section 5 ) and subject to such Holder entering into customary underwriting documentation for selling stockholders in an underwritten public offering in accordance with the requirements set forth in Section 3(b), and (ii) if, at any time after giving written notice of its intention to register any Registrable Securities pursuant to this Section 8(e) and prior to the effective date of the registration statement filed in connection with such registration, the Company shall determine for any reason not to cause such registration statement to become effective under the Securities Act, the Company shall deliver written notice to such Holder and, thereupon, shall be relieved of its obligation to register any Registrable Securities in connection with such registration (but not from its obligations to pay any expenses incurred in connection therewith in accordance with Section 5). The inclusion of any Registrable Securities in any Piggy-Back Registration Statement shall not constitute a waiver by any Holder of any rights such Holder may have by virtue of Section 8(a) being breached by the filing such Piggy-Back Registration Statement.
(ii) If the Company determines to proceed with any Underwritten Offering of Common Stock, whether on its own behalf or on behalf of any other stockholder of the Company, the Company shall so advise the Holders in writing, and each Holder shall have the right to have its Registrable Securities included in such Underwritten Offering and, in such event, the Company shall make such arrangements with the managing underwriter or underwriters so that such Holders may participate in such Underwritten Offering. If the offering pursuant is to be on any other basis, the Company shall so advise the Holders in writing and each Holder shall have the right to have its Registrable Securities included in such offering and the Company shall make such arrangements so that such Holder may participate in such offering.
(iii) If the managing underwriter or underwriters of any proposed Underwritten Offering of Registrable Securities informs the Company and the Holders that have requested to participate in such Underwritten Offering in writing that, in its or their opinion, the number of securities which such Holders and any other Persons intend to include in such offering exceeds the number which can be sold in such offering without being likely to have a significant adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, then the securities to be included in such Underwritten Offering shall be (i) first, 100% of the securities that the Company proposes to sell, and (ii) second, and only if all the securities referred to in clause (i) have been included, the number of Registrable Securities that, in the opinion of such managing underwriter or underwriters, can be sold without having such adverse effect on such offering, with such number to be allocated pro rata among such Holders that have requested to participate in such offering based on the relative number of Registrable
26
Securities then held by each such Holder (provided that any securities thereby allocated to a Holder that exceed such Holders request shall be reallocated among the remaining requesting Holders in like manner) and (iii) third, and only if all of the Registrable Securities referred to in clause (ii) have been included in such offering, any other securities eligible for inclusion in such offering that, in the opinion of the managing underwriter or underwriters, can be sold without having such adverse effect in such offering.
(f) Amendments and Waivers . The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of 75% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security); provided that, if any amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided , however , that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 8(f) . No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.
(g) Notices . Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile or email attachment at the facsimile number or email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or email address at the facsimile number or email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.
27
(h) Successors and Assigns . This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement. For the avoidance of doubt, the Lead Investor may assign, in whole or in part, its rights under this Agreement to (i) any transferee of its Registrable Securities upon such transferee executing a joinder to this Agreement as an additional Holder, and (ii) any of its Affiliates and its and its Affiliates respective members, stockholders, owners, equity holders and family members, in each case with respect to this clause (ii), that own any Common Stock.
(i) No Inconsistent Agreements . Neither the Company nor any of its Subsidiaries has entered, as of March 8, 2018, nor shall the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Except as set forth on Schedule 8(i), neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied in full. For the avoidance of doubt, neither the Original Agreement nor any provision thereof shall have any further force or effect.
(j) Execution and Counterparts . This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a .pdf format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof.
(k) Governing Law . All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective Affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Delaware for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
28
in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party hereto shall commence an Action or Proceeding to enforce any provisions of the this Agreement, then the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.
(l) Cumulative Remedies . The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.
(m) Severability . If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.
(n) Headings . The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof.
(o) Independent Nature of Holders Obligations and Rights . The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights,
29
including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any Proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.
********************
[ SIGNATURE PAGES FOLLOW ]
30
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.
COMPANY: | ||
ALPHATEC HOLDINGS, INC. | ||
By: |
/s/ JEFFREY BLACK |
|
Name: Jeffrey Black | ||
Title: Chief Financial Officer | ||
ADDRESS FOR NOTICE |
c/o: |
|
|
Street: |
|
City/State/Zip: |
|
Attention: |
|
Tel: |
|
|
Fax: |
|
|
Email: |
|
[ SIGNATURE PAGE OF COMPANY AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT ]
[ SIGNATURE PAGE OF HOLDERS FOLLOWS ]
Exhibit 99.1
SafeOp Surgical, Inc.
Financial Statements With Independent Auditors Report
Year Ended December 31, 2017
SafeOp Surgical, Inc.
Contents
Page | ||||
Independent Auditors Report |
1 | |||
Financial Statements: |
||||
Balance Sheet |
2 | |||
Statement of Operations |
3 | |||
Statement of Convertible Preferred Stock and Stockholders Deficit |
4 | |||
Statement of Cash Flows |
5 | |||
Notes to Financial Statements |
6 |
Independent Auditors Report
The Board of Directors
SafeOp Surgical, Inc.
Report on the Financial Statements
We have audited the accompanying financial statements of SafeOp Surgical, Inc. which comprise the balance sheet as of December 31, 2017, and the related statements of operations, convertible preferred stock and stockholders deficit, and cash flows for the year ended December 31, 2017, and the related notes to the financial statements.
Managements Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
Auditors Responsibility
Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Companys preparation of and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Companys internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting principles used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence that we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of SafeOp Surgical, Inc. as of December 31, 2017, and the results of its operations and its cash flows for the year ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.
Nanavaty, Nanavaty & Davenport, LLP
February 5, 2018
(April 16, 2018 as to Note 11)
-1-
|
SafeOp Surgical, Inc.
Balance Sheet
As of December 31, 2017
Assets | ||||
Assets: |
||||
Cash and cash equivalents |
$ | 300,581 | ||
Accounts receivable |
55,467 | |||
Inventory |
217,790 | |||
Prepaid expenses and other |
41,332 | |||
Equipment, net of accumulated depreciation |
22,905 | |||
Intangible asset, net of accumulated amortization |
240,625 | |||
|
|
|||
Total assets |
$ | 878,700 | ||
|
|
|||
Liabilities, Convertible Preferred Stock and Stockholders Deficit |
||||
Liabilities: |
||||
Accounts payable and accrued expenses |
$ | 221,428 | ||
Accrued compensation expense |
163,780 | |||
Convertible promissory notes |
2,400,858 | |||
|
|
|||
Total liabilities |
2,786,066 | |||
|
|
|||
Series A Preferred Stock, $0.0001 par value per share; 4,340,000 shares authorized, issued and outstanding |
4,340,000 | |||
Series B Preferred Stock, $0.0001 par value per share; 1,097,783 shares authorized, issued and outstanding |
2,470,012 | |||
Series C Preferred Stock, $0.0001 par value per share;12,455,767 shares authorized, 7,096,900 shares issued and outstanding |
4,511,018 | |||
Stockholders deficit: |
||||
Common stock, 0.0001 par value; 50,000,000 shares authorized, 8,274,708 shares issued and outstanding |
827 | |||
Stock warrants |
450 | |||
Additional paid-in-capital |
531,962 | |||
Retained deficit |
(13,761,635 | ) | ||
|
|
|||
Total stockholders deficit |
(13,228,396 | ) | ||
|
|
|||
Total liabilities, convertible preferred stock and stockholders deficit |
$ | 878,700 | ||
|
|
See accompanying notes to the financial statements.
-2-
SafeOp Surgical, Inc.
Statement of Operations
Year Ended December 31, 2017
Revenue |
$ | 246,485 | ||
Cost of goods sold |
123,038 | |||
|
|
|||
Gross profit |
123,447 | |||
|
|
|||
Research and development |
801,498 | |||
Sales and marketing |
1,342,701 | |||
General and administrative |
1,351,680 | |||
|
|
|||
Total operating expenses |
3,495,879 | |||
|
|
|||
Loss from operations |
(3,372,432 | ) | ||
Interest expense |
(13,358 | ) | ||
|
|
|||
Total other expense, net |
(13,358 | ) | ||
|
|
|||
Net loss |
$ | (3,385,790 | ) | |
|
|
See accompanying notes to the financial statements.
-3-
SafeOp Surgical, Inc.
Statement of Convertible Preferred Stock and Stockholders Deficit
Convertible Preferred Stock | Stockholders Deficit | |||||||||||||||||||||||||||||||||||||||||||||||
Series A Convertible | Series B Convertible | Series C Convertible | Additional | |||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock | Preferred Stock | Preferred Stock | Common Stock | paid-in | Retained | Stockholders | ||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Warrants | capital | deficit | deficit | |||||||||||||||||||||||||||||||||||||
Balance at December 31, 2016 |
4,340,000 | $ | 4,340,000 | 1,097,783 | $ | 2,470,012 | 7,096,900 | $ | 4,511,018 | 8,274,708 | $ | 827 | $ | 450 | $ | 340,830 | $ | (10,375,845 | ) | $ | (10,033,738 | ) | ||||||||||||||||||||||||||
Stock-based compensation |
| | | | | | | | | 191,132 | | 191,132 | ||||||||||||||||||||||||||||||||||||
Net loss |
| | | | | | | | | | (3,385,790 | ) | (3,385,790 | ) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2017 |
4,340,000 | $ | 4,340,000 | 1,097,783 | $ | 2,470,012 | 7,096,900 | $ | 4,511,018 | 8,274,708 | $ | 827 | $ | 450 | $ | 531,962 | $ | (13,761,635 | ) | $ | (13,228,396 | ) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to the financial statements.
-4-
SafeOp Surgical, Inc.
Year Ended December 31, 2017
Operating activities: |
||||
Net loss |
$ | (3,385,790 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
||||
Depreciation and amortization |
33,580 | |||
Stock-based compensation |
191,132 | |||
Noncash interest expense on convertible promissory notes |
13,358 | |||
Change in operating assets and liabilities: |
||||
Accounts receivable |
(46,164 | ) | ||
Inventory |
17,902 | |||
Prepaid expenses |
92,817 | |||
Accounts payable and accrued expenses |
(20,023 | ) | ||
Accrued compensation expense |
(203,448 | ) | ||
|
|
|||
Net cash used in operating activities |
(3,306,636 | ) | ||
|
|
|||
Investing activities: |
||||
Acquisition of equipment |
(6,822 | ) | ||
|
|
|||
Net cash used in investing activities |
(6,822 | ) | ||
|
|
|||
Financing activities: |
||||
Proceeds from issuance of convertible promissory notes |
2,387,500 | |||
|
|
|||
Net cash provided by financing activities |
2,387,500 | |||
|
|
|||
Net decrease in cash and cash equivalents |
(925,958 | ) | ||
Cash and cash equivalents, beginning of period |
1,226,539 | |||
|
|
|||
Cash and cash equivalents, end of period |
$ | 300,581 | ||
|
|
See accompanying notes to the financial statements.
-5-
SafeOp Surgical, Inc.
Notes to Financial Statements
1. |
Description of Business |
SafeOp Surgical, Inc., (the Company) was incorporated in the state of Delaware on September 30, 2011. The Company is a private biotech company focused on the commercializing of a medical device that automatically monitors and detects nerve abnormalities during surgeries. The Companys corporate office is in Hunt Valley, Maryland.
In January 2014, the Company received clearance from the Food and Drug Administration of the U.S. Department of Health and Human Services, to market its Evoked Potential Assessment Device (EPAD). The device is portable and intended for use in monitoring neurological status by recording somatosensory evoked potentials (SSEPs).
In 2016, the Company officially launched its product and began recording revenues. Prior to 2016, the Companys primary activities since incorporation were to establish its offices, recruit personnel, conduct research and development, perform business and financial planning, and raise capital.
2. |
Liquidity |
The accompanying financial statements have been prepared assuming the Company will continue as a going concern. Since inception the Company has reported losses from operations and is expected to generate losses and consume significant cash resources in the foreseeable future as the Company continues development of modules around the core product and continues to expand its sales channels. The Company has cash and cash equivalents of $300,581 and an accumulated deficit of $13,761,635 as of December 31, 2017. During 2017, the Company received bridge note financing of $2,387,500 in the form of convertible promissory notes. These promissory notes are convertible to Series D preferred stock. As part of the Series D Closing, the Company also plans to issue an additional 1,795,342 shares of Series D Preferred Stock raising $1,172,678 in additional funds. Management believes that cash and cash equivalents on hand at December 31, 2017 of $300,581, the funds raised by the Series D Closing, and cash flows from sales in 2018, will be sufficient to fund planned expenditures and meet the Companys obligations through part of 2018. However, there can be no assurance that additional financing will be available on satisfactory terms at all.
3. |
Significant Accounting Policies |
Basis of Presentation
The Companys financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate the continued existence of the Company.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from such estimates, and any difference could be material to the financial statements and accompanying notes.
Fair Value of Financial Instruments
The carrying amounts of the Companys financial instruments, which include cash and cash equivalents, prepaid expenses, accounts payable and accrued expenses generally approximate their respective fair value because of the short-term maturities.
-6-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
3. |
Significant Accounting Policies (continued) |
Cash and Cash Equivalents
Cash and cash equivalents are stated at fair value. The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains its cash in depository accounts that, at times, may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Sources of Supply
Many of the purchased components used to manufacture the Companys products are single-sourced due to technology, price, or other considerations. Some of these single-sourced components are manufactured to the Companys design and specifications. Most of these items, however, may be sourced from other suppliers, often after a requalification process. In the event that the Companys supply of critical components was interrupted due to the time required to requalify materials or modify product designs, the Companys ability to manufacture the related product in desired quantities and in a timely manner could be adversely affected. The Company attempts to mitigate these risks by working closely with key suppliers to coordinate product plans and the transition to replacement components for critical parts.
Inventories
Inventories consists primarily of finished goods, which includes specialized medical devices, and are stated at the lower of cost or market using the first-in, first-out cost method. The Company evaluates inventories for obsolescence and excess quantities based on changes in market demand or introduction of competing technologies.
Equipment and Depreciation
Equipment consists of computers, office equipment and furniture and is stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Expenditures for maintenance and repairs, which do not improve or extend the useful lives of the respective assets, are expensed as incurred.
Research and Development Expenses
Research and development costs are charged to expense as incurred. Research and development costs include the costs to design, develop, test, deploy and enhance its product. Costs incurred under agreements with third parties are charged to expense as incurred in accordance with the specific contractual performance terms of such agreements. Milestone payments incurred are charged to expense in accordance with the specific contractual performance terms of such agreements.
Intangible Asset
Intangible asset consists of purchased developed technology, which is amortized over a period of 20 years.
-7-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
3. |
Significant Accounting Policies (continued) |
Income Taxes
Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the tax bases of assets and liabilities and their reported amounts in the financial statements, as well as the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets and liabilities are measured at the balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted. The Company has incurred losses since September 30, 2011 (inception). Therefore, the Company has incurred no income tax liability and has not recorded any provision for income taxes.
The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon review by the relevant tax authorities. An uncertain income tax position will not be recognized if it is less than 50 percent likely of being sustained.
The Companys income tax returns are subject to examination by the appropriate taxing jurisdictions, and generally remain open for the last three years, as applicable.
Revenue Recognition
Revenue is derived from sale of goods and services associated with the EPAD device, and recognized upon delivery of such goods and services. Revenue is recorded at the fair value of the consideration received or receivable, excluding any trade discounts.
Accounts Receivable
Accounts receivable are stated at realizable value. Allowance for uncollectible amounts are based upon prior experience and aging. Receivables are reduced by this allowance, if any. All allowances and offsets are charged against revenue.
Stock-Based Compensation
The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Stock-based compensation expense is recognized ratably using the straight-line attribution method over the expected vesting period, which is considered to be the requisite service period. In addition, the Company is required to estimate the amount of expected forfeitures when calculating compensation expense. The Company accounts for nonemployee equity-based awards, in which services are the consideration received for the equity instruments issued, at their fair value.
For purposes of calculating the stock-based compensation expense, the fair value of the options granted by the Company in 2012 through 2016 was determined giving appropriate analysis to the preference of the Companys outstanding preferred stock, the Companys cash position and prior to 2016, its stage of development. Stock-based compensation expense recognized in the accompanying statements of operations for the year ended December 31, 2017, was further based on awards ultimately expected to vest and is reduced for estimated forfeitures, if any.
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model and straight-line amortization of compensation expense over the requisite service period of the grant.
-8-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
3. |
Significant Accounting Policies (continued) |
Subsequent Events
Management has evaluated transactions and events that occurred through February 5, 2018, the date that these financial statements were available to be issued, for recognition and/or disclosure in these financial statements.
4. |
Equipment |
Computer equipment |
$ | 40,596 | ||
Furniture |
15,309 | |||
|
|
|||
Subtotal |
55,905 | |||
Less: Accumulated depreciation |
(33,000 | ) | ||
|
|
|||
Equipment, net |
$ | 22,905 | ||
|
|
5. |
Intangible Asset |
Intangible asset consists of the following at December 31, 2017:
Weighted | ||||||||||||||||
Average | Gross | Net | ||||||||||||||
Useful Life | Carrying | Accumulated | Carrying | |||||||||||||
(In Years) | Amount | Amortization | Amount | |||||||||||||
Developed technology |
20 | $ | 350,000 | $ | (109,375 | ) | $ | 240,625 |
6. |
Convertible Preferred Stock |
In April 2016, the Company amended and restated its Certificate of Incorporation and certain Stockholders Agreements, to among other things increase the aggregate number of shares of all classes of stock of which the Corporation has the authority to issue to 67,893,550, designated as follows: (i) 50,000,000 shares of common stock, par value $0.0001 per share, and (ii) 17,893,550 shares of preferred stock, par value $0.0001 per share, of which 4,340,000 are designated Series A Preferred Stock, 1,097,783 are designated Series B Preferred Stock and 12,455,767 are designated Series C Preferred Stock. See Note 11 for more information on the January 2018 amendment to the Certificate of Incorporation.
Series A
The Company issued a total of 4,340,000 shares of Series A preferred stock with a price of $1 per share. The net cash proceeds of this financing was $4,340,000. The Companys Series A preferred stock has been classified as mezzanine on the balance sheet instead of stockholders equity in accordance with Accounting Standard Codification (ASC) 480-10-S99-3, Classification and Measurement of Redeemable Securities, under which if the preferred security holders control a majority of the votes of the Board of Directors through direct representation on the Board of Directors or through other rights, the preferred security is redeemable at the option of the holder, and its classification outside of permanent equity is appropriate. Accordingly, the Series A preferred stock is classified as other than permanent equity or mezzanine equity.
Conversion
Each share of Series A preferred stock may, at the option of the holder thereof, be converted at any time and from time to time, and without the payment of consideration by the holder thereof, into fully-paid and non-assessable shares of common stock, subject to anti-dilution adjustments. The number of shares of common stock which a Series A holder shall be entitled to receive upon conversion of its Series A preferred stock shall be equal to the product obtained by multiplying (a) the number of shares of Series A preferred stock being converted at any time by, (b) the conversion rate then in effect; or (c) upon a qualified public offering; or (d) upon the affirmative vote or consent of,
-9-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
6. |
Convertible Preferred Stock (continued) |
and written notice to, the Company by the holders of at least a majority of the then outstanding shares of Series A preferred stock.
Effective April 2016, in connection with the issuance of the Series C preferred stock, the conversion rights of the Series A preferred stock was changed from a 1:1 conversion rate to a 1:2.8868 conversion rate. At December 31, 2017, the total preferred stock issued and outstanding of 4,340,000 shares equals 12,528,868 common stock shares upon conversion.
The rights, preferences, and privileges of the preferred stock are as follows:
Voting
Each Series A preferred stock holder shall be entitled to vote together with the common stock and all other series and classes of stock permitted to vote with the common stock on all matters submitted to a vote of the holders of the common stock (including election of directors). For each vote in which the Series A holders are entitled to participate, each Series A holder shall be entitled to that number of votes per share to which such Series A holder would have been entitled had each share of Series A preferred stock held by such Series A holder then been converted into shares of common stock as specified in the Companys certificate of incorporation. The approval of Series A preferred stockholders is required for a number of significant changes to the Company, including creation of new classes of shares and amendments to the Companys Articles of Incorporation, election of the Companys board members, in addition to other corporate actions.
Dividends
Holders of Series A preferred stock shall be entitled to receive dividends out of any assets legally available only when as, and if declared by the Board of Directors, prior to and in preference to any declaration or payment of any dividend on the common stock, at a rate equal to 8% per annum (based upon a 365-day year) of $1.00 per share. Effective April 2016, the accreted value of such undeclared dividends were added to the liquidation value of the shares, and all further accretion has been cancelled. To date, the Board of Directors has not declared any dividends.
Liquidation
In the event of liquidation, dissolution, or winding up, whether voluntarily or involuntarily, and upon certain other defined events, the holders of the Series A preferred stock are also entitled to receive liquidation preferences in an amount per share of Series A preferred stock equal to (a) the Series A Issue Price plus, (b) an amount equal to all accrued and unpaid Series A dividends (whether or not declared) on such shares of Series A preferred stock. Liquidation payments are made in preference to any payments to the holders of common stock. At December 31, 2017, the total liquidation value of the Series A preferred stock is $5,698,512. If, upon liquidation, the available assets shall be insufficient to pay the full amount of the Series A liquidation preference, the Series A holders shall share in any distribution or payment of available assets pro rata in proportion to the respective Series A liquidation preference which would otherwise be payable upon a liquidation with respect to the outstanding shares of the Series A preferred stock if the Series A liquidation preference payable with respect to such shares were paid in full.
After payment in full of the Series A liquidation preference, the remaining available assets, if any, shall be distributed among the holders of the common stock pro rata in proportion to the number of shares of common stock then held by such holders.
Series B
In July through November 2014, the Company issued a total of 1,097,783 shares of Series B preferred stock with a price of $2.25 per share. The net cash proceeds received were $2,470,012. The Companys Series B preferred stock has been classified as mezzanine on the balance sheet instead of stockholders equity in accordance with Accounting
-10-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
6. |
Convertible Preferred Stock (continued) |
Standard Codification (ASC) 480-10-S99-3, Classification and Measurement of Redeemable Securities, under which if the preferred security holders control a majority of the votes of the Board of Directors through direct representation on the Board of Directors or through other rights, the preferred security is redeemable at the option of the holder, and its classification outside of permanent equity is appropriate. Accordingly, the Series B preferred stock is classified as other than permanent equity or mezzanine equity.
Conversion
Each share of Series B preferred stock may, at the option of the holder thereof, be converted at any time and from time to time, and without the payment of consideration by the holder thereof, into fully-paid and non-assessable shares of common stock, subject to anti-dilution adjustments. The number of shares of common stock which a Series B holder shall be entitled to receive upon conversion of its Series B preferred stock shall be equal to the product obtained by multiplying (a) the number of shares of Series B preferred stock being converted at any time by, (b) the conversion rate then in effect; or (c) upon a qualified public offering; or (d) upon the affirmative vote or consent of, and written notice to, the Company by the holders of at least a majority of the then outstanding shares of Series B preferred stock.
Effective April 2016, in connection with the issuance of the Series C preferred stock, the conversion rights of the Series B preferred stock was changed from a 1:1 conversion rate to a 1:3.96 conversion rate. At December 31, 2017, the total preferred stock issued and outstanding of 1,097,783 shares equals 4,347,082 common stock shares upon conversion.
The rights, preferences, and privileges of the preferred stock are as follows:
Voting
Each Series B preferred stock holder shall be entitled to vote together with the common stock and all other series and classes of stock permitted to vote with the common stock on all matters submitted to a vote of the holders of the common stock (including election of directors). For each vote in which the Series B holders are entitled to participate, each Series B holder shall be entitled to that number of votes per share to which such Series B holder would have been entitled had each share of Series B preferred stock held by such Series B holder then been converted into shares of common stock as specified in the Companys certificate of incorporation. The approval of Series B preferred stockholders is required for a number of significant changes to the Company, including creation of new classes of shares and amendments to the Companys Articles of Incorporation, election of the Companys board members, in addition to other corporate actions.
Dividends
Holders of Series B preferred stock shall be entitled to receive dividends out of any assets legally available only when as, and if declared by the Board of Directors, prior to and in preference to any declaration or payment of any dividend on the Series A preferred stock and the common stock, at a rate equal to 8% per annum (based upon a 365-day year) of $2.25 per share. Effective April 2016, the accreted value of such undeclared dividends were added to the liquidation value of the shares, and all further accretion has been cancelled. To date, the Board of Directors has not declared any dividends.
Liquidation
In the event of liquidation, dissolution, or winding up, whether voluntarily or involuntarily, and upon certain other defined events, the holders of the Series B preferred stock are also entitled to be paid out of the assets of the Company available for distribution or payment to holders of the Companys capital stock of all classes, before any distribution or payment is made to any holders of Series A preferred stock or common stock, an amount per share of Series B Preferred Stock equal to (a) the Series B Issue Price plus, (b) an amount equal to all accrued and unpaid Series B dividends (whether or not declared) on such shares of Series B preferred stock. Liquidation payments are made in preference to any payments to the holders of common stock. At December 31, 2017, the total liquidation
-11-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
6. |
Convertible Preferred Stock (continued) |
value of the Series B preferred stock is $2,819,448. If, upon liquidation, the available assets shall be insufficient to pay the full amount of the Series B liquidation preference, the Series B holders shall share in any distribution or payment of available assets pro rata in proportion to the respective Series B liquidation preference which would otherwise be payable upon a liquidation with respect to the outstanding shares of the Series B preferred stock if the Series B liquidation preference payable with respect to such shares were paid in full.
Series C
In April and June 2016, the Company issued a total of 7,096,900 shares of Series C preferred stock for net cash proceeds of $4,511,018. The Companys Series C preferred stock has been classified as mezzanine on the balance sheet instead of stockholders equity in accordance with Accounting Standard Codification (ASC) 480-10-S99-3, Classification and Measurement of Redeemable Securities, under which if the preferred security holders control a majority of the votes of the Board of Directors through direct representation on the Board of Directors or through other rights, the preferred security is redeemable at the option of the holder, and its classification outside of permanent equity is appropriate. Accordingly, the Series C preferred stock is classified as other than permanent equity or mezzanine equity.
Conversion
Each share of Series C preferred stock may, at the option of the holder thereof, be converted at any time and from time to time, and without the payment of consideration by the holder thereof, into fully-paid and non-assessable shares of common stock, subject to anti-dilution adjustments. The number of shares of common stock which a Series C holder shall be entitled to receive upon conversion of its Series C preferred stock shall be equal to the product obtained by multiplying (a) the number of shares of Series C preferred stock being converted at any time by, (b) the conversion rate then in effect, as defined in the Purchase Agreement.
The rights, preferences, and privileges of the preferred stock are as follows:
Voting
Each Series C preferred stock holder shall be entitled to vote together with the common stock and all other series and classes of stock permitted to vote with the common stock on all matters submitted to a vote of the holders of the common stock (including election of directors). For each vote in which the Series C holders are entitled to participate, each Series C holder shall be entitled to that number of votes per share to which such Series C holder would have been entitled had each share of Series C preferred stock held by such Series C holder then been converted into shares of common stock as specified in the Companys certificate of incorporation. The approval of Series C preferred stockholders is required for a number of significant changes to the Company, including creation of new classes of shares and amendments to the Companys Articles of Incorporation, election of the Companys board members, in addition to other corporate actions.
Dividends
Holders of Series C preferred stock shall be entitled to receive dividends out of any assets legally available only when as, and if declared by the Board of Directors. To date, the Board of Directors has not declared any dividends.
Liquidation
In the event of liquidation, dissolution, or winding up, whether voluntarily or involuntarily, and upon certain other defined events, the holders of the Series C preferred stock are also entitled to be paid out of the assets of the Company available for distribution or payment to holders of the Companys capital stock of all classes, before any distribution or payment is made to any holders of Series A or Series B preferred stock or common stock, an amount per share of Series C Preferred Stock held by such Series C holder equal to $4,511,018, subject to adjustment for any stock dividends, stock splits, and other subdivisions. If, upon liquidation, the available assets shall be
-12-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
6. |
Convertible Preferred Stock (continued) |
insufficient to pay the full amount of the Series C liquidation preference, the Series C holders shall share in any distribution or payment of available assets pro rata in proportion to the respective Series C liquidation preference which would otherwise be payable upon a liquidation with respect to the outstanding shares of the Series C preferred stock if the Series C liquidation preference payable with respect to such shares were paid in full.
7. |
Stockholders Deficit |
Common Stock: In connection with the sale of the Companys Series A preferred shares in the year ended December 31, 2012, the Company entered in an Award Agreement for Restricted Shares (the Agreement) with several common stockholders, including one employee/officer. In March 2012 a total of 900,000 shares of common stock were issued under the Agreement. At December 31, 2015, the entire 900,000 restricted shares granted became fully vested. During 2016, an additional 7,215,541 shares of common stock were issued under the Agreement. None of the awarded shares or any beneficial interest therein shall be transferred, encumbered, pledged or otherwise alienated or disposed of in any way until they have become non-forfeitable in accordance with the Agreement. Even after any of the awarded shares become transferable pursuant to this Agreement, they will remain subject to the transfer restrictions set forth in the Stockholders Agreement.
Common Stock Warrants: In connection with the April and June 2016 sale of the Companys Series C preferred shares, the Company granted 3,540,950 warrant shares to the Series C shareholders for the purchase of the Companys common stock at an exercise price of $.01 per share. The number of shares of common stock purchasable upon the exercise of this warrant is subject to adjustment from time to time upon the occurrence of certain events as described in the Warrant Agreement. The warrants allow for either a cash or share settlement at the sole discretion of the Company, and are only exercisable, whether in whole or in part, concurrently with the consummation of the Companys first firm commitment underwritten public offering of Warrant Shares which occurs before the expiration time of the warrants. The warrants expire upon the first to occur of (a) on June 30, 2026 and (b) the consummation of a liquidation of the Company.
The Company has a total of 50,000,000 shares of common stock authorized. The following shares of stock are issued or are reserved for future issuance:
Common stock outstanding under restricted stock awards |
8,274,708 | |||
Reserved for conversion of Series A preferred stock |
12,528,868 | |||
Reserved for conversion of Series B preferred stock |
4,347,082 | |||
Reserved for conversion of Series C preferred stock |
7,096,900 | |||
Reserved for exercise of stock options issued and outstanding |
582,203 | |||
Reserved for common stock warrants issued and outstanding |
3,540,950 | |||
Reserved for shares available for 2012 Equity Incentive Plan |
1,343,089 | |||
Common stock available for future issuance |
12,286,200 | |||
|
|
|||
Total authorized shares |
50,000,000 | |||
|
|
Stock Option Plan and Stock-Based Compensation
Stock Option Plan - Under the 2012 Equity Incentive Plan (the Plan) including amendments, 10,200,000 shares of common stock have been reserved for the issuance of incentive stock options (ISOs) and non-qualified stock options (NSOs). Employees, Directors, consultants, and other individuals who provide services to the Company are eligible to be granted Awards under the Plan; provided, however, that only employees of the Company are eligible to be granted ISOs. ISOs and NSOs may be granted with an exercise price no lesser than the fair market value of the common stock on the date of grant. Options granted to a 10% stockholder shall be at no less than 110% of the fair value, and ISO grants to such 10% stockholders expire five years from the date of grant. ISOs granted under the Plan generally vest 25% after completion of the first year of service, and the balance vest in equal monthly installments over the next 36 months of service and expire ten years from the grant date, unless subject to provisions regarding 10% stockholders. NSOs vest per the specific agreement and expire ten years from the date of grant.
-13-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
7. |
Stockholders Deficit (continued) |
The fair value of stock options granted was estimated using the following weighted average assumptions:
Expected dividend yield |
0.00 | % | ||
Expected term (in years) |
10 years | |||
Risk-free interest rate |
2.019 | % | ||
Expected stock price volatility |
100 | % |
The Company has not paid dividends on its common shares in the past nor does it expect to pay dividends in the future. As such, the company used a dividend yield percentage of zero. Additionally, because the Company does not have a publicly traded common stock, the expected volatility was estimated by the Company to be 100% consistent with the historical changes in the fair value of its stock price. The risk-free rates approximated the rate of treasury securities with the same term as the options on the date of the respective grant.
For the year ended, December 31, 2017, the Company recorded $191,132 of compensation expense related to stock options. As of December 31, 2017, there was $433,039 of total unrecognized cost related to non-vested stock option grants which is expected to be recognized over the next four years.
A summary of the 2012 Equity Incentive Plan activity is as follows:
Weighted | ||||||||||||||||
Outstanding | Average | |||||||||||||||
Available for | Outstanding | restricted | Exercise | |||||||||||||
Grant | Options | shares | Price | |||||||||||||
Balance at December 31, 2017 |
1,343,089 | 582,203 | 8,274,708 | $ | 0.0882 | |||||||||||
|
|
|
|
|
|
|
|
8. |
Income Taxes |
At December 31, 2017, the Company had federal and state net operating loss carryforwards of approximately $13,714,000 and $7,614,000, respectively. The difference between the federal and the state tax loss carryforwards is primarily attributable to the apportionment of income to various states. The Company also has federal research and development tax credit carryforwards of approximately $227,000 available to reduce future income subject to income taxes.
Significant components of the Companys deferred tax assets are shown below. A valuation allowance of $3,467,000 has been established as of December 31, 2017, to offset the deferred tax assets as realization of such assets does not meet the more likely than not threshold set forth in the standards.
Deferred tax assets: |
||||
Research and development credits |
$ | 48,000 | ||
State taxes |
(1,000 | ) | ||
Depreciation and amortization |
(8,000 | ) | ||
Net operating loss carryforwards |
3,428,000 | |||
|
|
|||
Total deferred tax assets |
3,467,000 | |||
Valuation allowance for deferred tax assets |
(3,467,000 | ) | ||
|
|
|||
Total net deferred tax assets |
$ | | ||
|
|
-14-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
9. |
Commitments |
The Company has entered into employment agreements with 5 of its key employees. The terms of the agreement include provisions for salary, bonuses, and benefits when certain measurable targets are achieved. In addition, the agreements include provisions that provide severance payments ranging from 75% to 100% of the employees annual base pay plus a pro rata portion of the performance bonus through the date of termination if the employees employment is terminated by the employer without cause or by the employee for good reason, or if there is a change in control (defined as greater than 50% of the Companys stock sold).
The Company has entered into a lease agreement for office space in Maryland. The initial lease term is for 37 months commencing December 2014, with an option for one additional 3-year term. Rent was initially $5,069 per month with scheduled increases of 3% per year. As an incentive to lease the office space the Company received 1 month rent-free. On November 17, 2017, the Company signed an amendment to the lease to extend the lease to March 31, 2021, at an annual rental of $60,817.85 paid in 12 equal monthly installments. The amendment includes a free-rental period of one month.
10. |
Convertible Promissory Notes |
During 2017, the Company issued a series of bridge notes in the form of convertible promissory notes (the notes) totaling $2,387,500. The notes accrue interest at various rates ranging from 1.01% to 1.52% per annum and mature in March 2018. The notes also have a conversion feature of 90% of the lowest price per share of the next equity securities in a Qualified Financing. At December 31, 2017, the Company has recorded $13,358 of interest expense on the notes. See Note 11 for more information on the issuance of the Series D preferred shares in exchange for the notes, subsequent to year-end.
11. |
Subsequent Events |
In January 2018, the Company issued a total of 4,082,528 shares of Series D preferred stock with an issue price of $.653178 per share, in exchange for principal and interest accrued through and including December 22, 2017 outstanding under the convertible promissory notes issued in 2017. The Company also sold 1,686,165 shares of Series D preferred stock for net cash proceeds of $1,101,366. The proceeds received by the Company from the sale of the shares at the Closings shall be used to fund the continued development of the Companys business and for general working capital purposes. Holders of the Series D preferred stock shall be entitled to dividends only when and if declared by the Board of Directors. Upon liquidation, holders of the Series D preferred stock are also entitled to be paid before holders of the Series C, B, or A Series preferred stock. Series D shares are convertible into shares of the Companys common stock at a rate 1:1.
As part of the Series D issue, the Company amended and restated its Certificate of Incorporation and certain Stockholders Agreements, to among other things increase the aggregate number of shares of all classes of stock of which the Corporation has the authority to issue to 68,412,553, designated as follows:
(i) 50,000,000 shares of common stock, par value $0.0001 per share, and (ii) 18,412,553 shares of preferred stock, par value $0.0001 per share, of which 4,340,000 are designated Series A Preferred Stock, 1,097,783 are designated Series B Preferred Stock, 7,096,900 are designated Series C Preferred Stock, and 5,877,870 are designated as Series D Preferred Stock.
On December 31, 2017, The Company received a Non-Binding Preliminary Indication of Interest to acquire all of its outstanding equity through a reverse triangular merger with a wholly-owned subsidiary of Alphatec Holdings, Inc. (Alphatec). The Company will be acquired on a cash-free and debt-free basis for total consideration of $34 million, subject to a Working Capital true-up, in cash, common stock, warrants, and a series of convertible promissory notes. The closing is contingent on due diligence procedures and expected to take place in the first quarter of 2018. During the due diligence period the Company will receive a daily ticking fee equal to $11,000 per day up to a maximum amount of $1 million.
On March 9, 2018, Alphatec announced its acquisition of the Company. Under the terms of the definitive merger agreement, Alphatec paid $15 million in cash, agreed to issued 3,265,132 shares of common stock, issued $3 million of convertible notes that are convertible into 931,667 shares of common stock and issued warrants to purchase 2.2
-15-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
11. |
Subsequent Events (continued) |
million shares of common stock at an exercise price of $3.50 per share. An additional 1,330,263 shares of common stock are issuable upon achievement of post-closing milestones.
-16-
SafeOp Surgical, Inc.
Financial Statements with Independent Auditors Report
Year Ended December 31, 2016
SafeOp Surgical, Inc.
Contents
Page | ||||
Independent Auditors Report |
1 | |||
Financial Statements: |
||||
Balance Sheet |
2 | |||
Statement of Operations |
3 | |||
Statement of Convertible Preferred Stock and Stockholders Deficit |
4 | |||
Statement of Cash Flows |
5 | |||
Notes to Financial Statements |
6 |
Independent Auditors Report
The Board of Directors
SafeOp Surgical, Inc.
Report on the Financial Statements
We have audited the accompanying financial statements of SafeOp Surgical, Inc. which comprise the balance sheet as of December 31, 2016, and the related statements of operations, convertible preferred stock and stockholders deficit, and cash flows for the year ended December 31, 2016, and the related notes to the financial statements.
Managements Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
Auditors Responsibility
Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Companys preparation of and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Companys internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting principles used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence that we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of SafeOp Surgical, Inc. as of December 31, 2016, and the results of its operations and its cash flows for the year ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America.
Nanavaty, Nanavaty & Davenport, LLP
February 16, 2017
-1-
SafeOp Surgical, Inc.
Balance Sheet
As of December 31, 2016
Assets | ||||
Assets: |
||||
Cash and cash equivalents |
$ | 1,226,539 | ||
Accounts receivable |
9,303 | |||
Inventory |
235,692 | |||
Prepaid expenses and other |
134,149 | |||
Equipment, net of accumulated depreciation |
32,163 | |||
Intangible asset, net of accumulated amortization |
258,125 | |||
|
|
|||
Total assets |
$ | 1,895,971 | ||
|
|
|||
Liabilities, Convertible Preferred Stock and Stockholders Deficit |
||||
Liabilities: |
||||
Accounts payable and accrued expenses |
$ | 241,451 | ||
Accrued compensation expense |
367,228 | |||
|
|
|||
Total liabilities |
608,679 | |||
|
|
|||
Series A Preferred Stock, $0.0001 par value per share; 4,340,000 shares authorized, issued and outstanding |
4,340,000 | |||
Series B Preferred Stock, $0.0001 par value per share; 1,097,783 shares authorized, issued and outstanding |
2,470,012 | |||
Series C Preferred Stock, $0.0001 par value per share; 12,455,767 shares authorized, 7,096,900 shares issued and outstanding |
4,511,018 | |||
Stockholders deficit: |
||||
Common stock, 0.0001 par value; 50,000,000 shares authorized, 8,274,708 shares issued and outstanding |
827 | |||
Stock warrants |
450 | |||
Additional paid-in-capital |
340,830 | |||
Retained deficit |
(10,375,845 | ) | ||
|
|
|||
Total stockholders deficit |
(10,033,738 | ) | ||
|
|
|||
Total liabilities, convertible preferred stock and stockholders deficit |
$ | 1,895,971 | ||
|
|
See accompanying notes to the financial statements.
-2-
SafeOp Surgical, Inc.
Statement of Operations
Year Ended December 31, 2016
Revenue |
$ | 61,143 | ||
Cost of goods sold |
183,582 | |||
|
|
|||
Gross profit |
(122,439 | ) | ||
|
|
|||
Research and development |
522,587 | |||
Sales and marketing |
985,073 | |||
General and administrative |
1,977,163 | |||
|
|
|||
Operating expenses |
3,484,823 | |||
|
|
|||
Loss from operations |
(3,607,262 | ) | ||
Interest income |
133 | |||
Interest expense |
(95,506 | ) | ||
|
|
|||
Total other expense, net |
(95,373 | ) | ||
|
|
|||
Net loss |
$ | (3,702,635 | ) | |
|
|
See accompanying notes to the financial statements.
-3-
SafeOp Surgical, Inc.
Statement of Convertible Preferred Stock and Stockholders Deficit
Convertible Preferred Stock | Stockholders Deficit | |||||||||||||||||||||||||||||||||||||||||||||||
Series A Convertible | Series B Convertible | Series C Convertible | Additional | |||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock | Preferred Stock | Preferred Stock | Common Stock | paid-in | Retained | Stockholders | ||||||||||||||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Warrants | capital | deficit | deficit | |||||||||||||||||||||||||||||||||||||
Balance at December 31, 2015 |
4,340,000 | $ | 4,340,000 | 1,097,783 | $ | 2,470,012 | | $ | | 900,000 | $ | 90 | $ | | $ | 166,570 | $ | (6,673,210 | ) | (6,506,550 | ) | |||||||||||||||||||||||||||
Conversion of Bridge notes to Series C convertible preferred stock in April 2016 |
| | | | 1,708,032 | 1,001,248 | | | | 99,939 | 99,939 | |||||||||||||||||||||||||||||||||||||
Issuance of Series C convertible preferred stock to stockholders in April 2016 |
| | | | 2,686,934 | 1,750,000 | | | | | | | ||||||||||||||||||||||||||||||||||||
Issuance of Series C convertible preferred stock to stockholders in June 2016 |
| | | | 2,686,934 | 1,750,000 | | | | | | | ||||||||||||||||||||||||||||||||||||
Issuance of common stock pursuant to restricted stock awards in May, June, October, and November 2016 |
| | | | | | 7,215,541 | 721 | | | | 721 | ||||||||||||||||||||||||||||||||||||
Issuance of common stock warrants in May and June 2016 |
| | | | | | | | 450 | | | 450 | ||||||||||||||||||||||||||||||||||||
Issuance of Series C convertible preferred stock to stockholder in September 2016 |
| | | | 15,000 | 9,770 | | | | | | | ||||||||||||||||||||||||||||||||||||
Issuance of common stock pursuant to restricted stock award in September 2016 |
| | | | | | 100,000 | 10 | | 9,990 | | 10,000 | ||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options in June 2016 |
| | | | | | 59,167 | 6 | | 586 | | 592 | ||||||||||||||||||||||||||||||||||||
Stock-based compensation |
| | | | | | | | | 63,745 | 63,745 | |||||||||||||||||||||||||||||||||||||
Net loss |
| | | | | | | | | | (3,702,635 | ) | (3,702,635 | ) | ||||||||||||||||||||||||||||||||||
Balance at December 31, 2016 |
4,340,000 | $ | 4,340,000 | 1,097,783 | $ | 2,470,012 | 7,096,900 | $ | 4,511,018 | 8,274,708 | $ | 827 | $ | 450 | $ | 340,830 | $ | (10,375,845 | ) | $ | (10,033,738 | ) |
See accompanying notes to the financial statements.
-4-
SafeOp Surgical, Inc.
Statement of Cash Flows
Year Ended December 31, 2016
Operating activities: |
||||
Net loss |
$ | (3,702,635 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
||||
Depreciation and amortization |
31,408 | |||
Stock-based compensation |
63,745 | |||
Noncash issuance of restricted common stock grant |
10,000 | |||
Noncash interest expense on convertible promissory notes |
95,506 | |||
Change in operating assets and liabilities: |
||||
Accounts receivable |
(9,303 | ) | ||
Inventory |
44,783 | |||
Prepaid expenses |
(119,139 | ) | ||
Accounts payable and accrued expenses |
(103,885 | ) | ||
Accrued compensation expense |
224,990 | |||
|
|
|||
Net cash used in operating activities |
(3,464,530 | ) | ||
|
|
|||
Investing activities: |
||||
Acquisition of equipment |
(18,976 | ) | ||
Write-off of computer software |
7,535 | |||
|
|
|||
Net cash used in investing activities |
(11,441 | ) | ||
|
|
|||
Financing activities: |
||||
Proceeds from issuance of promissory notes |
500,000 | |||
Issuance of common stock |
727 | |||
Issuance of common stock warrants |
450 | |||
Additional paid in capital |
100,525 | |||
Issuance of Series C convertible preferred stock |
3,409,830 | |||
|
|
|||
Net cash provided by financing activities |
4,011,532 | |||
|
|
|||
Net increase in cash and cash equivalents |
535,561 | |||
Cash and cash equivalents, beginning of period |
690,978 | |||
|
|
|||
Cash and cash equivalents, end of period |
$ | 1,226,539 | ||
|
|
|||
Supplemental Disclosure on Noncash Items: |
||||
Conversion of promissory notes and accrued interest into Series C convertible preferred stock |
$ | 1,001,248 | ||
Issuance of Series C convertible preferred stock |
$ | 9,770 |
See accompanying notes to the financial statements.
-5-
SafeOp Surgical, Inc.
Notes to Financial Statements
1. |
Description of Business |
SafeOp Surgical, Inc., (the Company) was incorporated in the state of Delaware on September 30, 2011. The Company is a private biotech company focused on the commercializing of a medical device that automatically monitors and detects nerve abnormalities during surgeries. The Companys corporate office is in Hunt Valley, Maryland.
In January 2014, the Company received clearance from the Food and Drug Administration of the U.S. Department of Health and Human Services, to market its Evoked Potential Assessment Device (EPAD). The device is portable and intended for use in monitoring neurological status by recording somatosensory evoked potentials (SSEPs).
In 2016, the Company officially launched its product and began collecting revenues. Prior to 2016, the Companys primary activities since incorporation were to establish its offices, recruit personnel, conduct research and development, perform business and financial planning, and raise capital.
2. |
Liquidity |
The accompanying financial statements have been prepared assuming the Company will continue as a going concern. Since inception the Company has reported losses from operations and is expected to generate losses and consume significant cash resources in the foreseeable future as the Company continues development of modules around the core product and begins to expand its business. The Company has cash and cash equivalents of $1,226,539 and an accumulated deficit of $10,375,845 as of December 31, 2016. During 2016, the Company completed the first two tranches of its Series C Closing raising $4,500,000 from the issuance of 7,096,900 shares of convertible Series C preferred stock. A total of $8,000,000 is planned to be raised from the Series C preferred stock financing. The remaining $3,500,000 is expected to close on or before December 31, 2017. Prior to 2016, the Company had completed its Series A and Series B Closings and received $4,340,000 and $2,470,012 in net proceeds from the sale of 4,340,000 and 1,097,783 shares of convertible Series A and B convertible preferred stock, respectively. Management believes that cash and cash equivalents on hand at December 31, 2016 of $1,226,539 in addition to $3,500,000 from the remainder of the Series C transaction in 2017, will be sufficient to fund planned expenditures and meet the Companys obligations through 2017. However, there can be no assurance that additional financing will be available on satisfactory terms at all.
3. |
Significant Accounting Policies |
Basis of Presentation
The Companys financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate the continued existence of the Company.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from such estimates, and any difference could be material to the financial statements and accompanying notes.
-6-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
3. |
Significant Accounting Policies (continued) |
Fair Value of Financial Instruments
The carrying amounts of the Companys financial instruments, which include cash and cash equivalents, prepaid expenses, accounts payable and accrued expenses generally approximate their respective fair value because of the short-term maturities.
Cash and Cash Equivalents
Cash and cash equivalents are stated at fair value. The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains its cash in depository accounts that, at times, may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Sources of Supply
Many of the purchased components used to manufacture the Companys products are single-sourced due to technology, price, or other considerations. Some of these single-sourced components are manufactured to the Companys design and specifications. Most of these items, however, may be sourced from other suppliers, often after a requalification process. In the event that the Companys supply of critical components was interrupted due to the time required to requalify materials or modify product designs, the Companys ability to manufacture the related product in desired quantities and in a timely manner could be adversely affected. The Company attempts to mitigate these risks by working closely with key suppliers to coordinate product plans and the transition to replacement components for critical parts.
Inventories
Inventories consists primarily of finished goods, which includes specialized medical devices, and are stated at the lower of cost or market using the first-in, first-out cost method. The Company evaluates inventories for obsolescence and excess quantities based on changes in market demand or introduction of competing technologies.
Equipment and Depreciation
Equipment consists of computers, office equipment and furniture and is stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Expenditures for maintenance and repairs, which do not improve or extend the useful lives of the respective assets, are expensed as incurred.
Research and Development Expenses
Research and development costs are charged to expense as incurred. Research and development costs include the costs to design, develop, test, deploy and enhance its product. Costs incurred under agreements with third parties are charged to expense as incurred in accordance with the specific contractual performance terms of such agreements. Milestone payments incurred are charged to expense in accordance with the specific contractual performance terms of such agreements.
Intangible Asset
Intangible asset consists of purchased developed technology, which is amortized over a period of 20 years.
-7-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
3. |
Significant Accounting Policies (continued) |
Income Taxes
Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the tax bases of assets and liabilities and their reported amounts in the financial statements, as well as the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets and liabilities are measured at the balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted. The Company has incurred losses since September 30, 2011 (inception). Therefore, the Company has incurred no income tax liability and has not recorded any provision for income taxes.
The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon review by the relevant tax authorities. An uncertain income tax position will not be recognized if it is less than 50 percent likely of being sustained.
The Companys income tax returns are subject to examination by the appropriate taxing jurisdictions, and generally remain open for the last three years, as applicable.
Stock-Based Compensation
The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Stock-based compensation expense is recognized ratably using the straight-line attribution method over the expected vesting period, which is considered to be the requisite service period. In addition, the Company is required to estimate the amount of expected forfeitures when calculating compensation expense. The Company accounts for nonemployee equity-based awards, in which services are the consideration received for the equity instruments issued, at their fair value.
For purposes of calculating the stock-based compensation expense, the fair value of the options granted by the Company in 2012 through 2016 was determined giving appropriate analysis to the preference of the Companys outstanding preferred stock, the Companys cash position and prior to 2016, its stage of development. Stock-based compensation expense recognized in the accompanying statements of operations for the year ended December 31, 2016, was further based on awards ultimately expected to vest and is reduced for estimated forfeitures, if any.
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model and straight-line amortization of compensation expense over the requisite service period of the grant.
Subsequent Events
Management has evaluated transactions and events that occurred through February 16, 2017, the date that these financial statements were available to be issued, for recognition and/or disclosure in these financial statements.
4. |
Equipment |
Computer equipment |
$ | 33,774 | ||
Furniture |
15,309 | |||
Subtotal |
49,083 | |||
Less: Accumulated depreciation |
(16,920 | ) | ||
Equipment, net |
$ | 32,163 |
-8-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
5. |
Intangible Asset |
Intangible asset consists of the following at December 31, 2016:
2015 | ||||||||||||||||
Weighted
Average Useful Life (In Years) |
Gross
Carrying Amount |
Accumulated
Amortization |
Net
Carrying Amount |
|||||||||||||
Developed technology |
20 | $ | 350,000 | $ | (91,875 | ) | $ | 258,125 |
6. |
Convertible Preferred Stock |
In April 2016, the Company amended and restated its Certificate of Incorporation and certain Stockholders Agreements, to among other things increase the aggregate number of shares of all classes of stock of which the Corporation has the authority to issue to 67,893,550, designated as follows: (i) 50,000,000 shares of common stock, par value $0.0001 per share, and (ii) 17,893,550 shares of preferred stock, par value $0.0001 per share, of which 4,340,000 are designated Series A Preferred Stock, 1,097,783 are designated Series B Preferred Stock and 12,455,767 are designated Series C Preferred Stock.
Series A
The Company issued a total of 4,340,000 shares of Series A preferred stock with a price of $1 per share. The net cash proceeds of this financing was $4,340,000. The Companys Series A preferred stock has been classified as mezzanine on the balance sheet instead of stockholders equity in accordance with Accounting Standard Codification (ASC) 480-10-S99-3, Classification and Measurement of Redeemable Securities, under which if the preferred security holders control a majority of the votes of the Board of Directors through direct representation on the Board of Directors or through other rights, the preferred security is redeemable at the option of the holder, and its classification outside of permanent equity is appropriate. Accordingly, the Series A preferred stock is classified as other than permanent equity or mezzanine equity.
Conversion
Each share of Series A preferred stock may, at the option of the holder thereof, be converted at any time and from time to time, and without the payment of consideration by the holder thereof, into fully-paid and non-assessable shares of common stock, subject to anti-dilution adjustments. The number of shares of common stock which a Series A holder shall be entitled to receive upon conversion of its Series A preferred stock shall be equal to the product obtained by multiplying (a) the number of shares of Series A preferred stock being converted at any time by, (b) the conversion rate then in effect; or (c) upon a qualified public offering; or (d) upon the affirmative vote or consent of, and written notice to, the Company by the holders of at least a majority of the then outstanding shares of Series A preferred stock.
Effective April 2016, in connection with the issuance of the Series C preferred stock, the conversion rights of the Series A preferred stock was changed from a 1:1 conversion rate to a 1:2.8868 conversion rate. At December 31, 2016, the total preferred stock issued and outstanding of 4,340,000 shares equals 12,528,868 common stock shares upon conversion.
The rights, preferences, and privileges of the preferred stock are as follows:
-9-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
6. |
Convertible Preferred Stock (continued) |
Voting
Each Series A preferred stock holder shall be entitled to vote together with the common stock and all other series and classes of stock permitted to vote with the common stock on all matters submitted to a vote of the holders of the common stock (including election of directors). For each vote in which the Series A holders are entitled to participate, each Series A holder shall be entitled to that number of votes per share to which such Series A holder would have been entitled had each share of Series A preferred stock held by such Series A holder then been converted into shares of common stock as specified in the Companys certificate of incorporation. The approval of Series A preferred stockholders is required for a number of significant changes to the Company, including creation of new classes of shares and amendments to the Companys Articles of Incorporation, election of the Companys board members, in addition to other corporate actions.
Dividends
Holders of Series A preferred stock shall be entitled to receive dividends out of any assets legally available only when as, and if declared by the Board of Directors, prior to and in preference to any declaration or payment of any dividend on the common stock, at a rate equal to 8% per annum (based upon a 365-day year) of $1.00 per share. Effective April 2016, the accreted value of such undeclared dividends were added to the liquidation value of the shares, and all further accretion has been cancelled. To date, the Board of Directors has not declared any dividends.
Liquidation
In the event of liquidation, dissolution, or winding up, whether voluntarily or involuntarily, and upon certain other defined events, the holders of the Series A preferred stock are also entitled to receive liquidation preferences in an amount per share of Series A preferred stock equal to (a) the Series A Issue Price plus, (b) an amount equal to all accrued and unpaid Series A dividends (whether or not declared) on such shares of Series A preferred stock. Liquidation payments are made in preference to any payments to the holders of common stock. At December 31, 2016, the total liquidation value of the Series A preferred stock is $5,698,512. If, upon liquidation, the available assets shall be insufficient to pay the full amount of the Series A liquidation preference, the Series A holders shall share in any distribution or payment of available assets pro rata in proportion to the respective Series A liquidation preference which would otherwise be payable upon a liquidation with respect to the outstanding shares of the Series A preferred stock if the Series A liquidation preference payable with respect to such shares were paid in full.
After payment in full of the Series A liquidation preference, the remaining available assets, if any, shall be distributed among the holders of the common stock pro rata in proportion to the number of shares of common stock then held by such holders.
Series B
In July through November 2014, the Company issued a total of 1,097,783 shares of Series B preferred stock with a price of $2.25 per share. The net cash proceeds received were $2,470,012. The Companys Series B preferred stock has been classified as mezzanine on the balance sheet instead of stockholders equity in accordance with Accounting Standard Codification (ASC) 480-10-S99-3, Classification and Measurement of Redeemable Securities, under which if the preferred security holders control a majority of the votes of the Board of Directors through direct representation on the Board of Directors or through other rights, the preferred security is redeemable at the option of the holder, and its classification outside of permanent equity is appropriate. Accordingly, the Series B preferred stock is classified as other than permanent equity or mezzanine equity.
-10-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
6. |
Convertible Preferred Stock (continued) |
Conversion
Each share of Series B preferred stock may, at the option of the holder thereof, be converted at any time and from time to time, and without the payment of consideration by the holder thereof, into fully-paid and non-assessable shares of common stock, subject to anti-dilution adjustments. The number of shares of common stock which a Series B holder shall be entitled to receive upon conversion of its Series B preferred stock shall be equal to the product obtained by multiplying (a) the number of shares of Series B preferred stock being converted at any time by, (b) the conversion rate then in effect; or (c) upon a qualified public offering; or (d) upon the affirmative vote or consent of, and written notice to, the Company by the holders of at least a majority of the then outstanding shares of Series B preferred stock.
Effective April 2016, in connection with the issuance of the Series C preferred stock, the conversion rights of the Series B preferred stock was changed from a 1:1 conversion rate to a 1:3.96 conversion rate. At December 31, 2016, the total preferred stock issued and outstanding of 1,097,783 shares equals 4,347,082 common stock shares upon conversion.
The rights, preferences, and privileges of the preferred stock are as follows:
Voting
Each Series B preferred stock holder shall be entitled to vote together with the common stock and all other series and classes of stock permitted to vote with the common stock on all matters submitted to a vote of the holders of the common stock (including election of directors). For each vote in which the Series B holders are entitled to participate, each Series B holder shall be entitled to that number of votes per share to which such Series B holder would have been entitled had each share of Series B preferred stock held by such Series B holder then been converted into shares of common stock as specified in the Companys certificate of incorporation. The approval of Series B preferred stockholders is required for a number of significant changes to the Company, including creation of new classes of shares and amendments to the Companys Articles of Incorporation, election of the Companys board members, in addition to other corporate actions.
Dividends
Holders of Series B preferred stock shall be entitled to receive dividends out of any assets legally available only when as, and if declared by the Board of Directors, prior to and in preference to any declaration or payment of any dividend on the Series A preferred stock and the common stock, at a rate equal to 8% per annum (based upon a 365-day year) of $1.00 per share. Effective April 2016, the accreted value of such undeclared dividends were added to the liquidation value of the shares, and all further accretion has been cancelled. To date, the Board of Directors has not declared any dividends.
Liquidation
In the event of liquidation, dissolution, or winding up, whether voluntarily or involuntarily, and upon certain other defined events, the holders of the Series B preferred stock are also entitled to be paid out of the assets of the Company available for distribution or payment to holders of the Companys capital stock of all classes, before any distribution or payment is made to any holders of Series A preferred stock or common stock, an amount per share of Series B Preferred Stock equal to (a) the Series B Issue Price plus, (b) an amount equal to all accrued and unpaid Series B dividends (whether or not declared) on such shares of Series B preferred stock. Liquidation payments are made in preference to any payments to the holders of common stock. At December 31, 2016, the total liquidation value of the Series B preferred stock is $2,819,448. If, upon liquidation, the available assets shall be insufficient to pay the full amount of the Series B liquidation preference, the Series B holders shall share in any distribution or payment of available assets pro rata in proportion to the respective Series B liquidation preference which would otherwise be payable upon a liquidation with respect to the outstanding shares of the Series B preferred stock if the Series B liquidation preference payable with respect to such shares were paid in full.
-11-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
6. |
Convertible Preferred Stock (continued) |
Series C
In April and June 2016, the Company issued a total of 7,096,900 shares of Series C preferred stock for net cash proceeds of $4,511,018. The Companys Series C preferred stock has been classified as mezzanine on the balance sheet instead of stockholders equity in accordance with Accounting Standard Codification (ASC) 480-10-S99-3, Classification and Measurement of Redeemable Securities, under which if the preferred security holders control a majority of the votes of the Board of Directors through direct representation on the Board of Directors or through other rights, the preferred security is redeemable at the option of the holder, and its classification outside of permanent equity is appropriate. Accordingly, the Series C preferred stock is classified as other than permanent equity or mezzanine equity.
Conversion
Each share of Series C preferred stock may, at the option of the holder thereof, be converted at any time and from time to time, and without the payment of consideration by the holder thereof, into fully-paid and non-assessable shares of common stock, subject to anti-dilution adjustments. The number of shares of common stock which a Series C holder shall be entitled to receive upon conversion of its Series C preferred stock shall be equal to the product obtained by multiplying (a) the number of shares of Series C preferred stock being converted at any time by, (b) the conversion rate then in effect, as defined in the Purchase Agreement.
The rights, preferences, and privileges of the preferred stock are as follows:
Voting
Each Series C preferred stock holder shall be entitled to vote together with the common stock and all other series and classes of stock permitted to vote with the common stock on all matters submitted to a vote of the holders of the common stock (including election of directors). For each vote in which the Series C holders are entitled to participate, each Series C holder shall be entitled to that number of votes per share to which such Series C holder would have been entitled had each share of Series C preferred stock held by such Series C holder then been converted into shares of common stock as specified in the Companys certificate of incorporation. The approval of Series C preferred stockholders is required for a number of significant changes to the Company, including creation of new classes of shares and amendments to the Companys Articles of Incorporation, election of the Companys board members, in addition to other corporate actions.
Dividends
Holders of Series C preferred stock shall be entitled to receive dividends out of any assets legally available only when as, and if declared by the Board of Directors. To date, the Board of Directors has not declared any dividends.
Liquidation
In the event of liquidation, dissolution, or winding up, whether voluntarily or involuntarily, and upon certain other defined events, the holders of the Series C preferred stock are also entitled to be paid out of the assets of the Company available for distribution or payment to holders of the Companys capital stock of all classes, before any distribution or payment is made to any holders of Series A or Series B preferred stock or common stock, an amount per share of Series C Preferred Stock held by such Series C holder equal to $4,511,018, subject to adjustment for any stock dividends, stock splits, and other subdivisions. If, upon liquidation, the available assets shall be insufficient to pay the full amount of the Series C liquidation preference, the Series C holders shall share in any distribution or payment of available assets pro rata in proportion to the respective Series C liquidation preference which would otherwise be payable upon a liquidation with respect to the outstanding shares of the Series C preferred stock if the Series C liquidation preference payable with respect to such shares were paid in full.
-12-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
7. |
Stockholders Deficit |
Common Stock: In connection with the sale of the Companys Series A preferred shares in the year ended December 31, 2012, the Company entered in an Award Agreement for Restricted Shares (the Agreement) with several common stockholders, including one employee/officer. In March 2012 a total of 900,000 shares of common stock were issued under the Agreement. At December 31, 2015, the entire 900,000 restricted shares granted became fully vested. During 2016, an additional 7,215,541 share of common stock were issued under the Agreement. None of the awarded shares or any beneficial interest therein shall be transferred, encumbered, pledged or otherwise alienated or disposed of in any way until they have become non-forfeitable in accordance with the Agreement. Even after any of the awarded shares become transferable pursuant to this Agreement, they will remain subject to the transfer restrictions set forth in the Stockholders Agreement.
Common Stock Warrants: In connection with the April and June 2016 sale of the Companys Series C preferred shares, the Company granted 3,540,950 warrant shares to the Series C shareholders for the purchase of the Companys common stock at an exercise price of $.01 per share. The amount of shares of common stock purchasable upon the exercise of this warrant is subject to adjustment from time to time upon the occurrence of certain events as described in the Warrant Agreement. The warrants allow for either a cash or share settlement at the sole discretion of the Company, and are only exercisable, whether in whole or in part, concurrently with the consummation of the Companys first firm commitment underwritten public offering of Warrant Shares which occurs before the expiration time of the warrants. The warrants expire upon the first to occur of (a) on June 30, 2026 and (b) the consummation of a liquidation of the Company.
The Company has a total of 50,000,000 shares of common stock authorized. The following shares of stock are issued or are reserved for future issuance:
Common stock outstanding under restricted stock awards |
8,274,708 | |||
Reserved for conversion of Series A preferred stock |
12,528,868 | |||
Reserved for conversion of Series B preferred stock |
4,347,082 | |||
Reserved for conversion of Series C preferred stock |
7,096,900 | |||
Reserved for exercise of stock options issued and outstanding |
582,203 | |||
Reserved for common stock warrants issued and outstanding |
3,540,950 | |||
Reserved for shares available for 2012 Equity Incentive Plan |
1,343,089 | |||
Common stock available for future issuance |
12,286,200 | |||
|
|
|||
Total authorized shares |
50,000,000 | |||
|
|
Stock Option Plan and Stock-Based Compensation
Stock Option Plan - Under the 2012 Equity Incentive Plan (the Plan) including amendments, 10,200,000 shares of common stock have been reserved for the issuance of incentive stock options (ISOs) and non-qualified stock options (NSOs). Employees, Directors, consultants, and other individuals who provide services to the Company are eligible to be granted Awards under the Plan; provided, however, that only employees of the Company are eligible to be granted ISOs. ISOs and NSOs may be granted with an exercise price no lesser than the fair market value of the common stock on the date of grant. Options granted to a 10% stockholder shall be at no less than 110% of the fair value, and ISO grants to such 10% stockholders expire five years from the date of grant. ISOs granted under the Plan generally vest 25% after completion of the first year of service, and the balance vest in equal monthly installments over the next 36 months of service and expire ten years from the grant date, unless subject to provisions regarding 10% stockholders. NSOs vest per the specific agreement and expire ten years from the date of grant.
-13-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
7. |
Stockholders Deficit (continued) |
The fair value of stock options granted was estimated using the following weighted average assumptions:
Expected dividend yield |
0.00 | % | ||
Expected term (in years) |
10 years | |||
Risk-free interest rate |
2.13 | % | ||
Expected stock price volatility |
100 | % |
The Company has not paid dividends on its common shares in the past nor does it expect to pay dividends in the future. As such, the company used a dividend yield percentage of zero. Additionally, because the Company does not have a publicly traded common stock, the expected volatility was estimated by the Company to be 100% consistent with the historical changes in the fair value of its stock price. The risk-free rates approximated the rate of treasury securities with the same term as the options on the date of the respective grant.
For the year ended, December 31, 2016, the Company recorded $63,745 of compensation expense related to stock options. As of December 31, 2016, there was $624,171 of total unrecognized cost related to non-vested stock option grants which is expected to be recognized over the next four years.
A summary of the 2012 Equity Incentive Plan activity is as follows:
Available for
Grant |
Outstanding
Options |
Outstanding
restricted shares |
Weighted
Average Exercise Price |
|||||||||||||
Balance at December 31, 2015 |
403,552 | 246,448 | 900,000 | $ | 0.0477 | |||||||||||
Reserved |
8,650,000 | | | $ | 0.1000 | |||||||||||
Granted |
(7,790,244 | ) | 474,703 | 7,315,541 | $ | 0.1000 | ||||||||||
Exercised |
| (59,167 | ) | 59,167 | $ | 0.1000 | ||||||||||
Forfeited or voided |
79,781 | (79,781 | ) | | $ | 0.0477 | ||||||||||
|
|
|
|
|
|
|||||||||||
Balance at December 31, 2016 |
1,343,089 | 582,203 | 8,274,708 | $ | 0.0882 | |||||||||||
|
|
|
|
|
|
8. |
Income Taxes |
At December 31, 2016, the Company had federal and state net operating loss carryforwards of approximately $10,347,000 and $4,762,000, respectively. The difference between the federal and the state tax loss carryforwards is primarily attributable to the apportionment of income to various states. The Company also has federal research and development tax credit carryforwards of approximately $168,000 available to reduce future income subject to income taxes.
Significant components of the Companys deferred tax assets are shown below. A valuation allowance of $4,021,000 has been established as of December 31, 2016, to offset the deferred tax assets as realization of such assets does not meet the more likely than not threshold set forth in the standards.
Deferred tax assets: |
||||
Research and development credits |
$ | 59,000 | ||
State taxes |
(2,000 | ) | ||
Depreciation and amortization |
(12,000 | ) | ||
Net operating loss carryforwards |
3,976,000 | |||
|
|
|||
Total deferred tax assets |
4,021,000 | |||
Valuation allowance for deferred tax assets |
(4,021,000 | ) | ||
|
|
|||
Total net deferred tax assets |
$ | | ||
|
|
-14-
SafeOp Surgical, Inc.
Notes to Financial Statements (continued)
9. |
Commitments |
The Company has entered into employment agreements with 5 of its key employees. The terms of the agreement include provisions for salary, bonuses, and benefits when certain measurable targets are achieved. In addition, the agreements include provisions that provide severance payments ranging from 75% to 100% of the employees annual base pay plus a pro rata portion of the performance bonus through the date of termination if the employees employment is terminated by the employer without cause or by the employee for good reason, or if there is a change in control (defined as greater than 50% of the Companys stock sold).
The Company has entered into a lease agreement for office space in Maryland. The initial lease term is for 37 months commencing December 2014, with an option for one additional 3-year term. Rent was initially $5,069 per month with scheduled increases of 3% per year. As an incentive to lease the office space the Company received 1 month rent-free.
-15-
Exhibit 99.2
Alphatec Holdings, Inc.
Unaudited Pro Forma Condensed Combined Financial Statements
On March 6, 2018, Alphatec Holdings, Inc. (the Company) and its newly-created wholly-owned subsidiary, Safari Merger Sub, Inc. (Sub), entered into an Agreement and Plan of Merger (the Merger Agreement) with SafeOp Surgical, Inc., a Delaware corporation (SafeOp), certain Key Stockholders of SafeOp and a Stockholder Representative. The Merger Agreement provides for a reverse triangular merger (the Merger), which was consummated on March 8, 2018, in which Sub was merged into SafeOp, with SafeOp being the surviving corporation and a wholly-owned subsidiary of the Company. Under the term of the Merger Agreement, the Company paid $15 million in cash, agreed to issue 3,265,132 shares of Common Stock, issued $3 million of notes that are convertible into 931,667 shares of Common Stock (the Notes), and issued warrants to purchase 2.2 million shares of Common Stock at an exercise price of $3.50 per share (the Merger Warrants). An additional 1,330,263 shares of Common Stock are issuable upon achievement of post-closing milestones.
The following unaudited pro forma condensed combined balance sheet as of December 31, 2017 and the unaudited pro forma condensed combined statements of operations for the year ended December 31, 2017 are based on the historical financial statements of the Company and SafeOp using the acquisition method of accounting.
The unaudited condensed combined pro forma balance sheet as of December 31, 2017 is based on the Companys consolidated balance sheet as of December 31, 2017 and SafeOps balance sheet as of December 31, 2017. The unaudited condensed combined pro forma balance sheet gives effect to the Merger and the completed and anticipated financing as if it had occurred on December 31, 2017, and includes all adjustments that give effect to events that are directly attributable to the Merger and are factually supportable. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2017 gives effect to the Merger and the completed and anticipated financing as if it had occurred on January 1, 2017 and includes all adjustments that give effect to events that are directly attributable to the Merger and the completed and anticipated financing, are expected to have a continuing impact, and are factually supportable.
The unaudited pro forma condensed combined financial statements are presented for informational purposes only and are not intended to represent or to be indicative of the results of operations and financial position that the Company would have reported had the Merger been completed as of the date set forth in the unaudited pro forma condensed combined financial statements.
The unaudited pro forma condensed combined financial statements reflect certain adjustments based on managements preliminary estimates of the fair values of tangible and intangible assets acquired. Upon completion of detailed valuation studies the Company may make additional adjustments to the fair values, and these valuations could change significantly from those used to determine certain adjustments in the pro forma condensed combined financial statements.
In addition to the Merger, the pro forma financial statements include the effect of entering into a securities purchase agreement dated March 8, 2018, pursuant to which the Company sold in a private placement (the Private Placement) to certain institutional and accredited investors (collectively, the Purchasers), including certain directors and executive officers of the Company, at a purchase price of $1,000 per share, 45,200 shares (the Preferred Shares) of newly designated Series B Convertible Preferred Stock (the Series B Convertible Preferred Stock) (which Preferred Shares will be converted into approximately 14,349,236 shares (subject to adjustment as described below and in the Certificate of Designations) of the Companys common stock (Common Stock) upon approval by the Companys stockholders (Stockholder Approval), and warrants to purchase up to 12,196,851 shares of Common Stock at an exercise price of $3.50 per share (the Private Offering Warrants). The Private Offering Warrants will become exercisable following Stockholder Approval, are subject to certain ownership limitations in certain cases, and expire five years after the date of such Stockholder Approval. The aggregate gross proceeds from the Private Placement were $45.2 million. The Company intends to use the net proceeds from the Private Placement for general corporate and working capital purposes and to fund strategic initiatives, including a portion of the Merger consideration described above.
The pro forma financial statements also include the effect of the Company entering into a Warrant Exercise Agreement (the Exercise Agreement) with Armistice Capital Master Fund, Ltd. (Armistice) on March 8, 2018, a holder of an outstanding warrant to purchase up to an aggregate of 2,400,000 shares of Common Stock, at an exercise price of $2.00 per share (the Original Warrant). Pursuant to the terms of the Exercise Agreement, Armistice has agreed to exercise, from time to time and in accordance with the terms of the Original Warrant, including certain beneficial ownership limitations set forth therein, the Original Warrant for cash (the Warrant Exercise). As a result of the Warrant Exercise, the Company received gross proceeds of $3.4 million on March 8, 2018 from the exercise of the 1.7 million shares of the Original Warrant, and expects to receive additional gross proceeds of up to $1.4 million thereafter from additional exercises of the remaining shares under the Original Warrant following Stockholder Approval. The Company expects to use the net proceeds from the exercise of the Original Warrant for general corporate and working capital purposes and to fund strategic initiatives.
These unaudited pro forma condensed combined financial statements should be read in conjunction with:
|
The Companys historical consolidated financial statements and notes thereto contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 9, 2018; |
|
The Companys Current Report on Form 8-K filed with the SEC on March 6, 2018; |
|
SafeOp Surgical Inc.s Financial Statements with Independent Auditors report for the year ended December 31, 2017 included in Appendix C. |
Alphatec Holdings, Inc.
Unaudited Pro Forma Condensed Combined Balance Sheet
As of December 31, 2017 (In thousands)
Alphatec
Historical |
SafeOp
Historical |
Pro Forma
Adjustments Financing |
Pro Forma
Adjustments SafeOp Acquisitions |
Pro Forma
Combined |
||||||||||||||||
Assets |
||||||||||||||||||||
Current assets: |
||||||||||||||||||||
Cash and cash equivalents |
$ | 22,466 | $ | 301 | $ | 47,797 | A | $ | (17,377 | )E | $ | 53,187 | ||||||||
Accounts receivable, net |
14,822 | 55 | 14,877 | |||||||||||||||||
Inventories |
27,292 | 218 | 27,510 | |||||||||||||||||
Prepaid expenses and other current assets |
1,767 | 41 | 1,808 | |||||||||||||||||
Current assets of discontinued operations |
131 | 131 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total current assets |
66,478 | 615 | 47,797 | (17,377 | ) | 97,513 | ||||||||||||||
Property and equipment, net |
12,670 | 23 | 12,693 | |||||||||||||||||
Intangible assets, net |
5,248 | 241 | 21,560 | F | 26,808 | |||||||||||||||
(241 | )G | |||||||||||||||||||
Goodwill |
12,148 | H | 12,148 | |||||||||||||||||
Other assets |
208 | 208 | ||||||||||||||||||
Noncurrent assets from discontinued operations |
56 | 56 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total assets |
$ | 84,660 | $ | 879 | $ | 47,797 | $ | 16,090 | $ | 149,426 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Liabilities And Stockholders Equity |
||||||||||||||||||||
Current liabilities: |
||||||||||||||||||||
Accounts payable |
$ | 3,878 | $ | 221 | $ | 386 | B | $ | 138 | I | $ | 4,561 | ||||||||
(62 | )J | |||||||||||||||||||
Accrued expenses |
22,246 | 164 | 62 | J | 22,472 | |||||||||||||||
Current portion of long-term debt |
3,306 | 3,306 | ||||||||||||||||||
Commitments and contingencies |
3,200 | K | 3,200 | |||||||||||||||||
Current liabilities of discontinued operations |
312 | 312 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total current liabilities |
29,742 | 385 | 386 | 3,338 | 33,851 | |||||||||||||||
Long-term debt less current portion |
37,767 | 3,000 | L | 40,767 | ||||||||||||||||
Other long-term debt |
20,206 | 20,206 | ||||||||||||||||||
Deferred tax liabilities |
2,189 | M | 2,189 | |||||||||||||||||
Convertible promissory note |
2,401 | (2,401 | )N | | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total liabilities |
87,715 | 2,786 | 386 | 6,126 | 97,013 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Redeemable preferred stock |
23,603 | 11,321 | (11,321 | )N | 23,603 | |||||||||||||||
Stockholders equity: |
||||||||||||||||||||
Series A convertible preferred stock |
| | | |||||||||||||||||
Series B convertible preferred stock |
| | | C | | |||||||||||||||
Common stock |
2 | 1 | | D | (1 | )O | 2 | |||||||||||||
| P | |||||||||||||||||||
Treasury Stock, 2 shares, at cost |
(97 | ) | (97 | ) | ||||||||||||||||
Additional paid in capital |
436,803 | 532 | 35,013 | C | (532 | )O | 487,978 | |||||||||||||
4,800 | D | 11,362 | P | |||||||||||||||||
Stock warrants |
1 | 7,598 | C | (1 | )O | 9,248 | ||||||||||||||
1,650 | Q | |||||||||||||||||||
Shareholder note receivable |
(5,000 | ) | (5,000 | ) | ||||||||||||||||
Accumulated other comprehensive income |
1,093 | 1,093 | ||||||||||||||||||
Accumulated deficit |
(459,459 | ) | (13,762 | ) | 13,762 | O | (464,414 | ) | ||||||||||||
(4,955 | )R | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total stockholders equity |
(26,658 | ) | (13,228 | ) | 47,411 | 21,285 | 28,810 | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total liabilities and stockholders equity |
$ | 84,660 | $ | 879 | $ | 47,797 | $ | 16,090 | $ | 149,426 | ||||||||||
|
|
|
|
|
|
|
|
|
|
Alphatec Holdings, Inc.
Unaudited Pro Forma Condensed Combined Statement of Operations
For the year ended December 31, 2017
(In thousands, except per share amounts)
Alphatec
Historical |
SafeOp
Historical |
Pro Forma
Adjustments Financing |
Pro Forma
Adjustments SafeOp Acquisitions |
Pro
Forma Combined |
||||||||||||||||
Revenues |
$ | 101,739 | $ | 246 | $ | | $ | | $ | 101,985 | ||||||||||
Cost of Revenues |
39,406 | 123 | 39,529 | |||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Gross Profit |
62,333 | 123 | 62,456 | |||||||||||||||||
Operating Expenses: |
||||||||||||||||||||
Research and development |
4,920 | 801 | 5,721 | |||||||||||||||||
Sales and marketing |
41,158 | 1,343 | 42,501 | |||||||||||||||||
General and administrative |
23,220 | 1,352 | (168 | )S | 24,404 | |||||||||||||||
Amortization of intangibles |
688 | 715 | F | 1,403 | ||||||||||||||||
Restructuring expenses |
2,206 | 2,206 | ||||||||||||||||||
Impairment on intangible assets |
(856 | ) | (856 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total costs and expenses |
71,336 | 3,496 | | 547 | 75,379 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Operating loss |
(9,003 | ) | (3,373 | ) | | (547 | ) | (12,923 | ) | |||||||||||
Interest expense, net |
(7,482 | ) | (13 | ) | (180 | )L | (7,675 | ) | ||||||||||||
Gain on change of fair value of warrants |
12,044 | 12,044 | ||||||||||||||||||
Other expenses, net |
(133 | ) | (133 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Loss from continuing operations before tax |
$ | (4,574 | ) | $ | (3,386 | ) | $ | | $ | (727 | ) | $ | (8,687 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Income tax benefit |
(34 | ) | (34 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Loss from continuing operations |
(4,540 | ) | (3,386 | ) | | (727 | ) | (8,653 | ) | |||||||||||
Income from discontinued operations, net |
2,246 | 2,246 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (2,294 | ) | $ | (3,386 | ) | $ | | $ | (727 | ) | $ | (6,407 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
(Loss) Income per share, basic: |
||||||||||||||||||||
Continuing operations |
$ | (0.36 | ) | $ | (0.47 | ) | ||||||||||||||
Discontinued operations |
0.18 | 0.12 | ||||||||||||||||||
|
|
|
|
|||||||||||||||||
Net loss per share, basic: |
$ | (0.18 | ) | $ | (0.35 | ) | ||||||||||||||
(Loss) Income per share, diluted: |
||||||||||||||||||||
Continuing operations |
$ | (1.25 | ) | $ | (0.42 | ) | ||||||||||||||
Discontinued operations |
0.17 | 0.05 | ||||||||||||||||||
|
|
|
|
|||||||||||||||||
Net loss per share, diluted |
$ | (1.08 | ) | $ | (0.38 | ) | ||||||||||||||
Weighted average number of shares outstanding: |
||||||||||||||||||||
Basic |
12,788 | 2,400 | T | 3,265 | T | 18,453 | ||||||||||||||
Diluted |
13,282 | 28,946 | U | 6,397 | U | 48,625 |
See the accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Statements, which are an integral part of these financial statements.
Alphatec Holdings, Inc.
Notes to Unaudited Pro Forma Condensed Combined Financial Statements
1. |
Description of Transaction and Basis of Presentation |
Description of Transaction
On March 6, 2018, Alphatec Holdings, Inc. (the Company) and its newly-created wholly-owned subsidiary, Safari Merger Sub, Inc. (Sub), entered into an Agreement and Plan of Merger (the Merger Agreement) with SafeOp Surgical, Inc., a Delaware corporation (SafeOp), certain Key Stockholders of SafeOp and a Stockholder Representative. The Merger Agreement provides for a reverse triangular merger (the Merger), which was consummated on March 8, 2018, in which Sub was merged into SafeOp, with SafeOp being the surviving corporation and a wholly-owned subsidiary of the Company. Under the terms of the Merger Agreement, the Company paid $15 million in cash, agreed to issue 3,265,132 shares of Common Stock, issued $3 million of notes that are convertible into 931,667 shares of Common Stock (the Notes), and issued warrants to purchase 2.2 million shares of Common Stock at an exercise price of $3.50 per share (the Merger Warrants). An additional 1,330,263 shares of Common Stock are issuable upon achievement of post-closing milestones.
In addition to the Merger, the pro forma financial statements include the effect of entering into a securities purchase agreement dated March 8, 2018, pursuant to which the Company sold in a private placement (the Private Placement) to certain institutional and accredited investors (collectively, the Purchasers), including certain directors and executive officers of the Company, at a purchase price of $1,000 per share, 45,200 shares (the Preferred Shares) of newly designated Series B Convertible Preferred Stock (the Series B Convertible Preferred Stock) (which Preferred Shares will be converted into approximately 14,349,236 shares (subject to adjustment as described below and in the Certificate of Designations) of the Companys common stock (Common Stock) upon approval by the Companys stockholders (Stockholder Approval), and warrants to purchase up to 12,196,851 shares of Common Stock at an exercise price of $3.50 per share (the Private Offering Warrants). The Private Offering Warrants will become exercisable following Stockholder Approval, are subject to certain ownership limitations in certain cases, and expire five years after the date of such Stockholder Approval. The aggregate gross proceeds from the Private Placement were approximately $45.2 million. The Company intends to use the net proceeds from the Private Placement for general corporate and working capital purposes and to fund strategic initiatives, including a portion of the Merger consideration described above.
The pro forma financial statements also include the effect of the Company entering into a Warrant Exercise Agreement (the Exercise Agreement) with Armistice Capital Master Fund, Ltd. (Armistice) on March 8, 2018, a holder of an outstanding warrant to purchase up to an aggregate of 2,400,000 shares of Common Stock, at an exercise price of $2.00 per share (the Original Warrant). Pursuant to the terms of the Exercise Agreement, Armistice has agreed to exercise, from time to time and in accordance with the terms of the Original Warrant, including certain beneficial ownership limitations set forth therein, the Original Warrant for cash (the Warrant Exercise). As a result of the Warrant Exercise, the Company received gross proceeds of $3.4 million on March 8, 2018 from the exercise of the 1.7 million shares of the Original Warrant, and expects to receive additional gross proceeds of up to $1.4 million thereafter from additional exercises of the remaining shares under the Original Warrant following Stockholder Approval. The Company expects to use the net proceeds from the exercise of the Original Warrant for general corporate and working capital purposes and to fund strategic initiatives.
Basis of Presentation
The unaudited pro forma condensed combined financial statement have been prepared based on the Companys and SafeOps historical financial information, giving effect to the Merger and related adjustments described in these notes. The Company and SafeOp prepares its financial statement in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Certain note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by the Securities and Exchange Commission rules and regulations.
The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2017, gives effect to the Merger and the completed and anticipated financing as if they were completed on January 1, 2017
and the unaudited pro forma condensed combined balance sheet as of December 31, 2017, gives effect to the Merger and the completed and anticipated financing as if they had occurred on that date.
The historical financial information is adjusted in the unaudited pro forma condensed combined financial information to give effect to pro forma events and are based on (i) the historical consolidated results of operations and financial condition of the Company; (ii) the historical consolidated results of operations and financial condition of SafeOp; and (iii) pro forma events directly attributable to the proposed merger and with respect to the unaudited condensed combined statements of operations are expected to have a continuing impact on the combined results, as further described below.
The Company accounts for business combinations in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 805, Business Combinations. The purchase price for the Merger has been allocated to the assets and liabilities acquired based on managements preliminary estimates of the fair values of tangible and intangible assets acquired. Upon completion of detailed valuation studies the Company may make additional adjustments to the fair values, and these valuations could change significantly from those used to determine certain adjustments in the pro forma condensed combined financial statements.
Certain reclassifications have been made to the historical presentation of SafeOp to conform to the presentation used in the unaudited pro forma condensed combined financial information. These reclassifications have no net impact on the historical operating loss, loss from continuing operations, total assets, liabilities, or shareholders equity reported by the Company or SafeOp.
2. |
Purchase Price |
In connection with the Merger, the Company agreed to pay $15 million in cash (subject to a working capital adjustment), agreed to issue 3,265,132 shares of Common Stock, issued Notes for $3 million, and issued Merger Warrants to purchase 2.2 million shares of Common Stock at an exercise price of $3.50 per share. In accordance with the terms of the Merger Agreement, the price per share of the Common Stock was based on the per share price at the time of entering into the Letter of Intent and the volume weighted average price per share of the Companys Common Stock for the period commencing on December 31, 2017 and ending March 5, 2018. For accounting purposes, such shares were valued as of March 8, 2018, at a per share price of $3.48; a total of $11.4 million. The Merger Warrants were fair valued at $1.6 million using the Black-Scholes valuation model. Additionally, a portion of the consideration transferred was to pay for certain SafeOp transaction costs incurred related to the Merger. As such, payments related to these reimbursements are excluded from the purchase price below.
The Company agreed to issue additional shares of Common Stock for up to $4.3 million upon achievement of post-closing milestones (the Contingent Consideration). The first milestone includes payment of up to $1.4 million 10 days after 501(k) submission of an application for regulatory clearance for an indication for use of a product that includes specifically recording of muscle activity, also known as electromyography (EMG). The second milestone includes a payment of up to $2.9 million 10 days after the receipt of 501(k) clearance from any regulatory authority for an indication for use of a product specifically EMG. The Contingent Consideration is recorded as a liability and measured at fair value using a probability-weighted income approach, utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate related to the risks of the expected cash flows attributable to the milestones. The material factors that may impact the fair value of the Contingent Consideration, and therefore, this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value, respectively. The fair value of the Contingent Consideration, and the associated liability relating to the Contingent Consideration at each reporting date, will be re-estimated with the changes in fair value reflected in earnings.
The total estimated purchase price is presented below (in thousands):
Cash |
$ | 13,272 | ||
Common Stock (net of $604 transaction costs paid) |
10,758 | |||
Note (net of $54 transaction costs paid) |
2,946 | |||
Warrants (net of $54 transaction costs paid) |
1,596 | |||
Contingent Consideration |
3,200 | |||
|
|
|||
Total |
$ | 31,772 | ||
|
|
Pro Forma Adjustments
A. |
Reflects the consideration received from the Private Placement and the Warrant Exercise, net of issuance costs paid to date summarized as follows (in thousands): |
Private Placement |
$ | 45,200 | ||
Issuance Costs |
(2,203 | ) | ||
Warrant Exercise |
4,800 | |||
|
|
|||
Total |
$ | 47,797 | ||
|
|
B. |
Reflects the amount of the Private Placement issuance costs that were incurred but not yet paid as of the issuance date. |
C. |
Reflects the issuance of 45,200 shares of Series B Convertible Preferred Stock with a par value of $0.0001 and the Private Offering Warrants, net of issuance costs. The total consideration received of $45.2 million and the issuance costs incurred of $2.3 million is allocated to the Series B Convertible Preferred Stock and the Private Offering Warrants on a relative fair value basis. |
Par Value | APIC | |||||||
Series B Convertible Preferred Stock |
$ | | $ | 37,140 | ||||
Series B Convertible Preferred Stock Issuance Costs |
(2,127 | ) | ||||||
|
|
|
|
|||||
Total |
$ | | $ | 35,013 | ||||
|
|
|
|
|||||
Private Offering Warrants |
| 8,060 | ||||||
Private Offering Warrants Issuance Costs |
(462 | ) | ||||||
|
|
|
|
|||||
Total |
$ | | $ | 7,598 | ||||
|
|
|
|
D. |
Reflects the issuance of 2,400,000 shares of Common Stock with a par value of $0.0001 for $2 per share related to the Warrant Exercise (in thousands). |
Par value | APIC | |||||||
Common Stock |
$ | | $ | 4,800 |
E. |
Reflects the amount of cash consideration paid for the Merger, plus cash paid for transaction related costs as follows (in thousands): |
Cash consideration |
$ | 13,272 | ||
The Companys transaction costs |
3,351 | |||
SafeOps transaction costs |
754 | |||
|
|
|||
Total |
$ | 17,377 | ||
|
|
The cash paid for the Companys transaction costs includes $1.8 million paid on behalf of SafeOp.
F. |
Reflects fair value adjustments for intangibles acquired in the Merger and related pro forma amortization adjustments. Pro forma amortization expense is based on an estimated useful life of one year for the EPAD Tradename. The in-process research and development (IPR&D) for the EMG technology is considered to have an indefinite life until the development is completed (i.e. once FDA clearance is obtained), at which point the Company will determine the intangible assets estimated useful life. The intangible assets acquired in the Merger are detailed below (in thousands): |
Fair
Value |
Remaining
Useful Life (Years) |
Pro Forma
Amortization Expense |
||||||||||
EPAD Tradename |
$ | 60 | 1 | $ | 60 | |||||||
IPR&D |
8,400 | N/A | ||||||||||
Developed technology |
13,100 | 20 | 655 | |||||||||
|
|
|
|
|||||||||
Total |
$ | 21,560 | $ | 715 | ||||||||
|
|
|
|
G. |
Reflects the elimination of SafeOps historical intangible asset value. |
H. |
Reflects the estimated amount of goodwill to be recorded (in thousands): |
Purchase Price |
$ | 31,772 | ||
Less: Estimated fair value of the assets acquired: |
||||
Current assets |
(615 | ) | ||
Property and equipment |
(23 | ) | ||
EPAD 1 tradename |
(60 | ) | ||
IPR&D - EMG |
(8,400 | ) | ||
Developed technology SSEP |
(13,100 | ) | ||
Plus: Estimated fair value of the liabilities assumed |
||||
Current liabilities |
385 | |||
Deferred tax liability |
2,189 | |||
|
|
|||
Goodwill |
$ | 12,148 | ||
|
|
I. |
Reflects the amount of the Merger transaction costs that were incurred but not yet paid as of the transaction date. |
J. |
Represents a reclassification of SafeOp accrued expenses from accounts payable into a separate line item, consistent with the Companys presentation. |
K. |
Reflects the estimated fair value of the Contingent Consideration (refer to Note 2). |
L. |
Reflects the Notes issued as part of the consideration transferred and related estimated interest (in thousands). The Company determined that the issuance costs were not material and expensed the costs as incurred. |
Value |
Annual
Interest Rate |
Interest
Expense |
||||||||||
Note |
$ | 3,000 | 6 | % | $ | 180 |
M. |
Reflects the deferred tax liability recorded as part of the acquisition of the IPR&D. |
N. |
Reflects the conversion of the SafeOp convertible promissory notes and redeemable preferred stock into SafeOp equity prior to the Merger. |
O. |
Reflects the elimination of SafeOps shareholders equity. These adjustments include the net effect of converting the SafeOp convertible promissory notes and redeemable preferred stock into equity plus the elimination of those equity amounts. |
P. |
Reflects the issuance of 3,265,132 shares of Common Stock with a par value of $0.0001 and a closing price of $3.48, as part of the consideration transferred (refer to Note 2) (in thousands). |
Par Value | APIC | |||||||
Common Stock |
$ | | $ | 11,362 |
Q. |
Reflects the issuance of the warrants as part of the consideration transferred (refer to Note 2). |
R. |
Reflects the recognition of transaction expense incurred as part of the Merger as follows (in thousands): |
Cash |
$ | 4,105 | ||
Accounts Payable |
138 | |||
Common Stock |
604 | |||
Note |
54 | |||
Merger Warrants |
54 | |||
|
|
|||
Total |
$ | 4,955 | ||
|
|
S. |
Reflects the elimination of transaction expenses related to the Merger recognized in the historical financial statements. |
T. |
Reflects the changes in the basic shares outstanding for the shares of Common Stock issued as part of the Warrant Exercise and Merger (in thousands). |
Pro forma basic weighted average shares |
||||
Historical weighted average shares outstanding |
12,788 | |||
Shares issued from Warrant Exercise |
2,400 | |||
Shares issued as part of Merger consideration |
3,265 | |||
|
|
|||
Pro forma weighted average shares (basic) |
18,453 | |||
|
|
U. |
Reflects the changes in the diluted shares outstanding for the issuance of the Series B Convertible Preferred Stock, the Private Placement Warrants, the Notes, and the Merger Warrants (in thousands). |
Pro forma diluted weighted average shares |
||||
Historical weighted average shares outstanding |
13,282 | |||
Shares issued from Warrant Exercise |
2,400 | |||
Shares issues as part of Merger consideration |
3,265 | |||
Shares converted from Series B Convertible Preferred |
14,349 | |||
Shares converted from Private Placement Warrants |
12,197 | |||
Shares converted from Notes |
932 | |||
Shares converted from Merger Warrants |
2,200 | |||
|
|
|||
Pro forma weighted average shares (diluted) |
48,625 | |||
|
|
Income Taxes
Due to the Companys ongoing operating losses, and the resulting inability to recognize any income tax benefit, there is no provision for income taxes in the pro forma condensed combined financial statement.